{"id":"carboplatin","rwe":[{"pmid":"41899495","year":"2026","title":"Obesity and Tolerance to Neoadjuvant Chemotherapy in Breast Cancer: A Retrospective Cohort Study.","finding":"","journal":"Cancers","studyType":"Clinical Study"},{"pmid":"41899267","year":"2026","title":"Primary Peritoneal Low-Grade Serous Carcinoma in a 16-Year-Old Female: A Case Report.","finding":"","journal":"Journal of clinical medicine","studyType":"Clinical Study"},{"pmid":"41898678","year":"2026","title":"NRF2 Drives Aggressiveness and Chemoresistance in Ovarian Cancer Stem-like Cells.","finding":"","journal":"International journal of molecular sciences","studyType":"Clinical Study"},{"pmid":"41898390","year":"2026","title":"Radiobiological Effects of Low-Dose Radiation in Normal Fibroblasts of Patients with Head and Neck Cancer Treated with Induction Chemotherapy Combined with Low-Dose Fractionated Radiation.","finding":"","journal":"International journal of molecular sciences","studyType":"Clinical Study"},{"pmid":"41897350","year":"2026","title":"Metformin-A Type 2 Diabetes Mellitus Drug-And Ovarian Cancer: Anticancer Mechanisms and Therapeutic Implications.","finding":"","journal":"Biomolecules","studyType":"Clinical Study"}],"_fda":{"id":"0e68e276-b0df-4f03-e063-6394a90a22b9","set_id":"1c275825-0275-4c73-b650-e4c1519f13b8","openfda":{"nui":["N0000175413","N0000175073"],"upc":["0360505628261","0360505628230","0360505628278"],"unii":["BG3F62OND5"],"route":["INTRAVENOUS"],"rxcui":["597195"],"spl_id":["0e68e276-b0df-4f03-e063-6394a90a22b9"],"brand_name":["CARBOPLATIN"],"spl_set_id":["1c275825-0275-4c73-b650-e4c1519f13b8"],"package_ndc":["60505-6282-1","60505-6282-3","60505-6282-6","60505-6282-7"],"product_ndc":["60505-6282"],"generic_name":["CARBOPLATIN"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["CARBOPLATIN"],"pharm_class_epc":["Platinum-based Drug [EPC]"],"manufacturer_name":["Apotex Corp."],"application_number":["ANDA077861"],"is_original_packager":[true]},"version":"2","warnings":["WARNINGS Bone marrow suppression (leukopenia, neutropenia, and thrombocytopenia) is dose-dependent and is also the dose-limiting toxicity. Peripheral blood counts should be frequently monitored during carboplatin injection treatment and, when appropriate, until recovery is achieved. Median nadir occurs at day 21 in patients receiving single agent carboplatin. In general, single intermittent courses of carboplatin should not be repeated until leukocyte, neutrophil, and platelet counts have recovered. Since anemia is cumulative, transfusions may be needed during treatment with carboplatin, particularly in patients receiving prolonged therapy. Bone marrow suppression is increased in patients who have received prior therapy, especially regimens including cisplatin. Marrow suppression is also increased in patients with impaired kidney function. Initial carboplatin injection dosages in these patients should be appropriately reduced (see DOSAGE AND ADMINISTRATION ) and blood counts should be carefully monitored between courses. The use of carboplatin in combination with other bone marrow suppressing therapies must be carefully managed with respect to dosage and timing in order to minimize additive effects. Carboplatin has limited nephrotoxic potential, but concomitant treatment with aminoglycosides has resulted in increased renal and/or audiologic toxicity, and caution must be exercised when a patient receives both drugs. Clinically significant hearing loss has been reported to occur in pediatric patients when carboplatin was administered at higher than recommended doses in combination with other ototoxic agents. Carboplatin can induce emesis, which can be more severe in patients previously receiving emetogenic therapy. The incidence and intensity of emesis have been reduced by using premedication with antiemetics. Although no conclusive efficacy data exist with the following schedules of carboplatin, lengthening the duration of single intravenous administration to 24 hours or dividing the total dose over 5 consecutive daily pulse doses has resulted in reduced emesis. Although peripheral neurotoxicity is infrequent, its incidence is increased in patients older than 65 years and in patients previously treated with cisplatin. Pre-existing cisplatin-induced neurotoxicity does not worsen in about 70% of the patients receiving carboplatin as secondary treatment. Loss of vision, which can be complete for light and colors, has been reported after the use of carboplatin with doses higher than those recommended in the package insert. Vision appears to recover totally or to a significant extent within weeks of stopping these high doses. As in the case of other platinum-coordination compounds, allergic reactions to carboplatin have been reported. These may occur within minutes of administration and should be managed with appropriate supportive therapy. There is increased risk of allergic reactions including anaphylaxis in patients previously exposed to platinum therapy. (See CONTRAINDICATIONS and ADVERSE REACTIONS: Allergic Reactions .) High dosages of carboplatin (more than 4 times the recommended dose) have resulted in severe abnormalities of liver function tests. Carboplatin injection may cause fetal harm when administered to a pregnant woman. Carboplatin has been shown to be embryotoxic and teratogenic in rats. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant."],"overdosage":["OVERDOSAGE There is no known antidote for carboplatin injection overdosage. The anticipated complications of overdosage would be secondary to bone marrow suppression and/or hepatic toxicity."],"description":["DESCRIPTION Carboplatin injection is supplied as a sterile, pyrogen-free, 10 mg/mL aqueous solution of carboplatin, USP. It is available in multiuse vials containing 50 mg/5 mL, 150 mg/15 mL, and 450 mg/45 mL or 600 mg/60 mL of carboplatin, USP. Inactive ingredients include water for injection, USP. The pH of the solution ranges from 5.0 to 7.0. Carboplatin, USP is a platinum coordination compound. The chemical name for carboplatin, USP is platinum, diammine [1, 1- cyclobutanedicarboxylato (2- )-0, 0']-, (SP- 4-2), and carboplatin, USP has the following structural formula: Carboplatin, USP is a crystalline powder. It is soluble in water at a rate of approximately 14 mg/mL, and the pH of a 1% solution is 5 to 7. It is virtually insoluble in ethanol, acetone, and dimethylacetamide. image"],"how_supplied":["HOW SUPPLIED Each mL of carboplatin injection contains 10 mg of carboplatin, USP in water for injection, USP and is available in individual cartons as follows: NDC Number Contents Size 60505-6282-1 50 mg 5 mL multidose vial 60505-6282-3 150 mg 15 mL multidose vial 60505-6282-6 450 mg 45 mL multidose vial 60505-6282-7 600 mg 60 mL multidose vial"],"boxed_warning":["Carboplatin injection should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate treatment facilities are readily available. Bone marrow suppression is dose related and may be severe, resulting in infection and/or bleeding. Anemia may be cumulative and may require transfusion support. Vomiting is another frequent drug related side effect. Anaphylactic-like reactions to carboplatin have been reported and may occur within minutes of carboplatin injection administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms."],"effective_time":"20240107","clinical_studies":["CLINICAL STUDIES Use with Cyclophosphamide for Initial Treatment of Ovarian Cancer In two prospectively randomized, controlled studies conducted by the National Cancer Institute of Canada, Clinical Trials Group (NCIC) and the Southwest Oncology Group (SWOG), 789 chemotherapy naive patients with advanced ovarian cancer were treated with carboplatin or cisplatin, both in combination with cyclophosphamide every 28 days for 6 courses before surgical reevaluation. The following results were obtained from both studies: Comparative Efficacy Overview of Pivotal Trials NCIC SWOG Number of patients randomized 447 342 Median age (years) 60 62 Dose of cisplatin 75 mg/m 2 100 mg/m 2 Dose of carboplatin 300 mg/m 2 300 mg/m 2 Dose of cyclophosphamide 600 mg/m 2 600 mg/m 2 Residual tumor < 2 cm (number of patients) 39% (174/447) 14% (49/342) Clinical Response in Measurable Disease Patients NCIC SWOG Carboplatin (number of patients) 60% (48/80) 58% (48/83) Cisplatin (number of patients) 58% (49/85) 43% (33/76) 95% CI of difference (Carboplatin-Cisplatin) (-13.9%, 18.6%) (-2.3%, 31.1%) Pathologic Complete Response * * 114 Carboplatin and 109 Cisplatin patients did not undergo second look surgery in NCIC study. 90 Carboplatin and 106 Cisplatin patients did not undergo second look surgery in SWOG study. NCIC SWOG Carboplatin (number of patients) 11% (24/224) 10% (17/171) Cisplatin (number of patients) 15% (33/223) 10% (17/171) 95% CI of difference (Carboplatin-Cisplatin) (-10.7%, 2.5%) (-6.9%, 6.9%) Progression-Free Survival (PFS) * Kalpan-Meier Estimates Unrelated deaths occurring in the absence of progression were counted as events (progression) in this analysis. * * Analysis adjusted for factors found to be of prognostic significance were consistent with unadjusted analysis. NCIC SWOG Median Carboplatin 59 weeks 49 weeks Cisplatin 61 weeks 47 weeks 2 - year PFS * Carboplatin 31% 21% Cisplatin 31% 21% 95% CI of difference (Carboplatin-Cisplatin) (-9.3, 8.7) (-9, 9.4) 3 - year PFS * Carboplatin 19% 8% Cisplatin 23% 14% 95% CI of difference (Carboplatin-Cisplatin) (-11.5, 4.5) (-14.1, 0.3) Hazard Ratio * * 1.10 1.02 95% CI (Carboplatin-Cisplatin) (0.89, 1.35) (0.81, 1.29) Survival * Kaplan-Meier Estimates * * Analysis adjusted for factors found to be of prognostic significance were consistent with unadjusted analysis. NCIC SWOG Median Carboplatin 110 weeks 86 weeks Cisplatin 99 weeks 79 weeks 2 - year Survival * Carboplatin 51.9% 40.2% Cisplatin 48.4% 39.0% 95% CI of difference (Carboplatin-Cisplatin) (-6.2, 13.2) (-9.8, 12.2) 3 - year Survival * Carboplatin 34.6% 18.3% Cisplatin 33.1% 24.9% 95% CI of difference (Carboplatin-Cisplatin) (-7.7, 10.7) (-15.9, 2.7) Hazard Ratio * 95% CI 0.98 1.01 (Carboplatin–Cisplatin) (0.78, 1.23) (0.78, 1.30) Comparative Toxicity The pattern of toxicity exerted by the carboplatin-containing regimen was significantly different from that of the cisplatin-containing combinations. Differences between the two studies may be explained by different cisplatin dosages and by different supportive care. The carboplatin-containing regimen induced significantly more thrombocytopenia and, in one study, significantly more leukopenia and more need for transfusional support. The cisplatin-containing regimen produced significantly more anemia in one study. However, no significant differences occurred in incidences of infections and hemorrhagic episodes Non-hematologic toxicities (emesis, neurotoxicity, ototoxicity, renal toxicity, hypomagnesemia, and alopecia) were significantly more frequent in the cisplatin-containing arms. ADVERSE EXPERIENCES IN PATIENTS WITH OVARIAN CANCER NCIC STUDY * Values are in percent of evaluable patients. * * ns = not significant, p>0.05 † May have been affected by cyclophosphamide dosage delivered Carboplatin Arm Percent * Cisplatin Arm Percent * P - Values * * Bone Marrow Thrombocytopenia <100,000/mm 3 70 29 <0.001 <50,000/mm 3 41 6 <0.001 Neutropenia <2,000 cells/mm 3 97 96 ns <1,000 cells/mm 3 81 79 ns Leukopenia <4,000 cells/mm 3 98 97 ns <2,000 cells/mm 3 68 52 0.001 Anemia <11 g/dL 91 91 ns <8 g/dL 18 12 ns Infections 14 12 ns Bleeding 10 4 ns Transfusions 42 31 0.018 Gastrointestinal Nausea and vomiting 93 98 0.010 Vomiting 84 97 <0.001 Other GI side effects 50 62 0.013 Neurologic Peripheral neuropathies 16 42 <0.001 Ototoxicity 13 33 <0.001 Other sensory side effects 6 10 ns Central neurotoxicity 28 40 0.009 Renal Serum creatinine elevations 5 13 0.006 Blood urea elevations 17 31 <0.001 Hepatic Bilirubin elevations 5 3 ns SGOT elevations 17 13 ns Alkaline phosphatase elevations - - - Electrolytes loss Sodium 10 20 0.005 Potassium 16 22 ns Calcium 16 19 ns Magnesium 63 88 <0.001 Other side effects Pain 36 37 ns Asthenia 40 33 ns Cardiovascular 15 19 ns Respiratory 8 9 ns Allergic 12 9 ns Genitourinary 10 10 ns Alopecia † 50 62 0.017 Mucositis 10 9 ns ADVERSE EXPERIENCES IN PATIENTS WITH OVARIAN CANCER SWOG STUDY * Values are in percent of evaluable patients. * * ns = not significant, p>0.05 † May have been affected by cyclophosphamide dosage delivered Carboplatin Arm Percent * Cisplatin Arm Percent * P - Values * * Bone Marrow Thrombocytopenia <100,000/mm 3 59 35 <0.001 <50,000/mm 3 22 11 0.006 Neutropenia <2,000 cells/mm 3 95 97 ns <1,000 cells/mm 3 84 78 ns Leukopenia <4,000 cells/mm 3 97 97 ns <2,000 cells/mm 3 76 67 ns Anemia <11 g/dL 88 87 ns <8 g/dL 8 24 <0.001 Infections 18 21 ns Bleeding 6 4 ns Transfusions 25 33 ns Gastrointestinal Nausea and vomiting 94 96 ns Vomiting 82 91 0.007 Other GI side effects 40 48 ns Neurologic Peripheral neuropathies 13 28 0.001 Ototoxicity 12 30 <0.001 Other sensory side effects 4 6 ns Central neurotoxicity 23 29 ns Renal Serum creatinine elevations 7 38 <0.001 Blood urea elevations - - - Hepatic Bilirubin elevations 5 3 ns SGOT elevations 23 16 ns Alkaline phosphatase elevations 29 20 ns Electrolytes loss Sodium - - - Potassium - - - Calcium - - - Magnesium 58 77 <0.001 Other side effects Pain 54 52 ns Asthenia 43 46 ns Cardiovascular 23 30 ns Respiratory 12 11 ns Allergic 10 11 ns Genitourinary 11 13 ns Alopecia † 43 57 0.009 Mucositis 6 11 ns Use as a Single Agent for Secondary Treatment of Advanced Ovarian Cancer In two prospective, randomized controlled studies in patients with advanced ovarian cancer previously treated with chemotherapy, carboplatin achieved 6 clinical complete responses in 47 patients. The duration of these responses ranged from 45 to 71+ weeks."],"adverse_reactions":["ADVERSE REACTIONS To report SUSPECTED ADVERSE REACTIONS Contact Apotex Corp.at 1-800-706-5575 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . For a comparison of toxicities when carboplatin or cisplatin was given in combination with cyclophosphamide, see CLINICAL STUDIES : Use with Cyclophosphamide for Initial Treatment of Ovarian Cancer: Comparative Toxicity. ADVERSE EXPERIENCES IN PATIENTS WITH OVARIAN CANCER * Use with Cyclophosphamide for Initial Treatment of Ovarian Cancer: Data are based on the experience of 393 patients with ovarian cancer (regardless of baseline status) who received initial combination therapy with carboplatin and cyclophosphamide in two randomized controlled studies conducted by SWOG and NCIC (see CLINICAL STUDIES ). Combination with cyclophosphamide as well as duration of treatment may be responsible for the differences that can be noted in the adverse experience table. * * Single Agent Use for the Secondary Treatment of Ovarian Cancer: Data are based on the experience of 553 patients with previously treated ovarian carcinoma (regardless of baseline status) who received single agent carboplatin. First Line Combination Therapy * Percent Second Line Single Agent Therapy * * Percent Bone Marrow Thrombocytopenia <100,000/mm3 66 62 <50,000/mm3 33 35 Neutropenia <2,000 cells/mm3 96 67 <1,000 cells/mm3 82 21 Leukopenia <4,000 cells/mm3 97 85 <2,000 cells/mm3 71 26 Anemia <11 g/dL 90 90 <8g/dL 14 21 Infections 16 5 Bleeding 8 5 Transfusions 35 44 Gastrointestinal Nausea and vomiting 93 92 Vomiting 83 81 Other GI side effects 46 21 Neurologic Peripheral neuropathies 15 6 Ototoxicity 12 1 Other sensory side effects 5 1 Central neurotoxicity 26 5 Renal Serum creatinine elevations 6 10 Blood urea elevations 17 22 Hepatic Bilirubin elevations 5 5 SGOT elevations 20 19 Alkaline phosphatase elevations 29 37 Electrolytes loss Sodium 10 47 Potassium 16 28 Calcium 16 31 Magnesium 61 43 Other side effects Pain 44 23 Asthenia 41 11 Cardiovascular 19 6 Respiratory 10 6 Allergic 11 2 Genitourinary 10 2 Alopecia 49 2 Mucositis 8 1 In the narrative section that follows, the incidences of adverse events are based on data from 1,893 patients with various types of tumors who received carboplatin as single agent therapy. Hematologic Toxicity Bone marrow suppression is the dose-limiting toxicity of carboplatin. Thrombocytopenia with platelet counts below 50,000/mm 3 occurs in 25% of the patients (35% of pretreated ovarian cancer patients); neutropenia with granulocyte counts below 1,000/mm 3 occurs in 16% of the patients (21% of pretreated ovarian cancer patients); leukopenia with WBC counts below 2,000/mm 3 occurs in 15% of the patients (26% of pretreated ovarian cancer patients). The nadir usually occurs about day 21 in patients receiving single agent therapy. By day 28, 90% of patients have platelet counts above 100,000/mm 3 ; 74% have neutrophil counts above 2,000/mm 3 ; 67% have leukocyte counts above 4,000/mm 3 . Marrow suppression is usually more severe in patients with impaired kidney function. Patients with poor performance status have also experienced a higher incidence of severe leukopenia and thrombocytopenia. The hematologic effects, although usually reversible, have resulted in infectious or hemorrhagic complications in 5% of the patients treated with carboplatin, with drug related death occurring in less than 1% of the patients. Fever has also been reported in patients with neutropenia. Anemia with hemoglobin less than 11 g/dL has been observed in 71% of the patients who started therapy with a baseline above that value. The incidence of anemia increases with increasing exposure to carboplatin. Transfusions have been administered to 26% of the patients treated with carboplatin (44% of previously treated ovarian cancer patients). Bone marrow depression may be more severe when carboplatin is combined with other bone marrow suppressing drugs or with radiotherapy. Gastrointestinal Toxicity Vomiting occurs in 65% of the patients (81% of previously treated ovarian cancer patients) and in about one-third of these patients it is severe. Carboplatin, as a single agent or in combination, is significantly less emetogenic than cisplatin; however, patients previously treated with emetogenic agents, especially cisplatin, appear to be more prone to vomiting. Nausea alone occurs in an additional 10% to 15% of patients. Both nausea and vomiting usually cease within 24 hours of treatment and are often responsive to antiemetic measures. Although no conclusive efficacy data exist with the following schedules, prolonged administration of carboplatin, either by continuous 24-hour infusion or by daily pulse doses given for 5 consecutive days, was associated with less severe vomiting than the single-dose intermittent schedule. Emesis was increased when carboplatin was used in combination with other emetogenic compounds. Other gastrointestinal effects observed frequently were pain, in 17% of the patients; diarrhea, in 6%; and constipation, also in 6%. Neurologic Toxicity Peripheral neuropathies have been observed in 4% of the patients receiving carboplatin (6% of pretreated ovarian cancer patients) with mild paresthesias occurring most frequently. Carboplatin therapy produces significantly fewer and less severe neurologic side effects than does therapy with cisplatin. However, patients older than 65 years and/or previously treated with cisplatin appear to have an increased risk (10%) for peripheral neuropathies. In 70% of the patients with pre-existing cisplatin-induced peripheral neurotoxicity, there was no worsening of symptoms during therapy with carboplatin. Clinical ototoxicity and other sensory abnormalities such as visual disturbances and change in taste have been reported in only 1% of the patients. Central nervous system symptoms have been reported in 5% of the patients and appear to be most often related to the use of antiemetics. Although the overall incidence of peripheral neurologic side effects induced by carboplatin is low, prolonged treatment, particularly in cisplatin pretreated patients, may result in cumulative neurotoxicity. Nephrotoxicity Development of abnormal renal function test results is uncommon, despite the fact that carboplatin, unlike cisplatin, has usually been administered without high-volume fluid hydration and/or forced diuresis. The incidences of abnormal renal function tests reported are 6% for serum creatinine and 14% for blood urea nitrogen (10% and 22%, respectively, in pretreated ovarian cancer patients). Most of these reported abnormalities have been mild and about one-half of them were reversible. Creatinine clearance has proven to be the most sensitive measure of kidney function in patients receiving carboplatin, and it appears to be the most useful test for correlating drug clearance and bone marrow suppression. Twenty-seven percent of the patients who had a baseline value of 60 mL/min or more demonstrated a reduction below this value during carboplatin therapy. Hepatic Toxicity The incidences of abnormal liver function tests in patients with normal baseline values were reported as follows: total bilirubin, 5%; SGOT, 15%; and alkaline phosphatase, 24%; (5%, 19%, and 37%, respectively, in pretreated ovarian cancer patients). These abnormalities have generally been mild and reversible in about one-half of the cases, although the role of metastatic tumor in the liver may complicate the assessment in many patients. In a limited series of patients receiving very high dosages of carboplatin and autologous bone marrow transplantation, severe abnormalities of liver function tests were reported. Electrolyte Changes The incidences of abnormally decreased serum electrolyte values reported were as follows: sodium, 29%; potassium, 20%; calcium, 22%; and magnesium, 29%; (47%, 28%, 31%, and 43%, respectively, in pretreated ovarian cancer patients). Electrolyte supplementation was not routinely administered concomitantly with carboplatin, and these electrolyte abnormalities were rarely associated with symptoms. Allergic Reactions Hypersensitivity to carboplatin has been reported in 2% of the patients. These allergic reactions have been similar in nature and severity to those reported with other platinum-containing compounds, ie, rash, urticaria, erythema, pruritus, and rarely bronchospasm and hypotension. Anaphylactic reactions have been reported as part of postmarketing surveillance (see WARNINGS ). These reactions have been successfully managed with standard epinephrine, corticosteroid, and antihistamine therapy. Injection Site Reactions Injection site reactions, including redness, swelling, and pain, have been reported during postmarketing surveillance. Necrosis associated with extravasation has also been reported. Other Events Pain and asthenia were the most frequently reported miscellaneous adverse effects; their relationship to the tumor and to anemia was likely. Alopecia was reported (3%). Cardiovascular, respiratory, genitourinary, and mucosal side effects have occurred in 6% or less of the patients. Cardiovascular events (cardiac failure, embolism, cerebrovascular accidents) were fatal in less than 1% of the patients and did not appear to be related to chemotherapy. Cancer-associated hemolytic uremic syndrome has been reported rarely. Malaise, anorexia, hypertension, dehydration, and stomatitis have been reported as part of postmarketing surveillance."],"contraindications":["CONTRAINDICATIONS Carboplatin injection is contraindicated in patients with a history of severe allergic reactions to cisplatin or other platinum-containing compounds. Carboplatin injection should not be employed in patients with severe bone marrow depression or significant bleeding."],"how_supplied_table":["
NDC NumberContentsSize
60505-6282-150 mg 5 mL multidose vial
60505-6282-3150 mg 15 mL multidose vial
60505-6282-6450 mg 45 mL multidose vial
60505-6282-7600 mg60 mL multidose vial
"],"storage_and_handling":["STORAGE Unopened vials of carboplatin injection are stable to the date indicated on the package when stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. PROTECT FROM LIGHT. Carboplatin injection multidose vials maintain microbial, chemical, and physical stability for up to 14 days at 25°C following multiple needle entries. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Solutions for infusion should be discarded 8 hours after preparation."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Carboplatin, like cisplatin, produces predominantly interstrand DNA cross-links rather than DNA-protein cross-links. This effect is apparently cell-cycle nonspecific. The aquation of carboplatin, which is thought to produce the active species, occurs at a slower rate than in the case of cisplatin. Despite this difference, it appears that both carboplatin and cisplatin induce equal numbers of drug-DNA cross-links, causing equivalent lesions and biological effects. The differences in potencies for carboplatin and cisplatin appear to be directly related to the difference in aquation rates. In patients with creatinine clearances of about 60 mL/min or greater, plasma levels of intact carboplatin decay in a biphasic manner after a 30-minute intravenous infusion of 300 mg/m 2 to 500 mg/m 2 of carboplatin. The initial plasma half-life (alpha) was found to be 1.1 to 2 hours (n=6), and the postdistribution plasma half-life (beta) was found to be 2.6 to 5.9 hours (n=6). The total body clearance, apparent volume of distribution and mean residence time for carboplatin are 4.4 L/hour, 16 L and 3.5 hours, respectively. The C max values and areas under the plasma concentration versus time curves from 0 to infinity (AUC inf) increase linearly with dose, although the increase was slightly more than dose proportional. Carboplatin, therefore, exhibits linear pharmacokinetics over the dosing range studied (300 mg/m 2 to 500 mg/m 2 ). Carboplatin is not bound to plasma proteins. No significant quantities of protein-free, ultrafilterable platinum-containing species other than carboplatin are present in plasma. However, platinum from carboplatin becomes irreversibly bound to plasma proteins and is slowly eliminated with a minimum half-life of 5 days. The major route of elimination of carboplatin is renal excretion. Patients with creatinine clearances of approximately 60 mL/min or greater excrete 65% of the dose in the urine within 12 hours and 71% of the dose within 24 hours. All of the platinum in the 24-hour urine is present as carboplatin. Only 3% to 5% of the administered platinum is excreted in the urine between 24 and 96 hours. There are insufficient data to determine whether biliary excretion occurs. In patients with creatinine clearances below 60 mL/min, the total body and renal clearances of carboplatin decrease as the creatinine clearance decreases. Carboplatin dosages should therefore be reduced in these patients (see DOSAGE AND ADMINISTRATION ). The primary determinant of carboplatin injection clearance is glomerular filtration rate (GFR) and this parameter of renal function is often decreased in elderly patients. Dosing formulas incorporating estimates of GFR (see DOSAGE AND ADMINISTRATION ) to provide predictable carboplatin injection plasma AUCs should be used in elderly patients to minimize the risk of toxicity."],"indications_and_usage":["INDICATIONS Initial Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of carboplatin and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see CLINICAL STUDIES ). There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor < 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. Secondary Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate."],"warnings_and_cautions":["PRECAUTIONS General Needles or intravenous administration sets containing aluminium parts that may come in contact with carboplatin injection should not be used for the preparation or administration of the drug. Aluminium can react with carboplatin causing precipitate formation and loss of potency. Drug Interactions The renal effects of nephrotoxic compounds may be potentiated by carboplatin. Carcinogenesis, Mutagenesis, Impairment of Fertility The carcinogenic potential of carboplatin has not been studied, but compounds with similar mechanisms of action and mutagenicity profiles have been reported to be carcinogenic. Carboplatin has been shown to be mutagenic both in vitro and in vivo . It has also been shown to be embryotoxic and teratogenic in rats receiving the drug during organogenesis. Secondary malignancies have been reported in association with multi-drug therapy. Pregnancy Pregnancy Category D See WARNINGS . Nursing Mothers It is not known whether carboplatin is excreted in human milk. Because there is a possibility of toxicity in nursing infants secondary to carboplatin treatment of the mother, it is recommended that breast-feeding be discontinued if the mother is treated with carboplatin injection. Pediatric Use Safety and effectiveness in pediatric patients have not been established (see WARNINGS: \"audiologic toxicity\"). Geriatric Use Of the 789 patients in initial treatment combination therapy studies (NCIC and SWOG), 395 patients were treated with carboplatin in combination with cyclophosphamide. Of these, 141 were over 65 years of age and 22 were 75 years or older. In these trials, age was not a prognostic factor for survival. In terms of safety, elderly patients treated with carboplatin were more likely to develop severe thrombocytopenia than younger patients. In a combined database of 1,942 patients (414 were ≥ 65 years of age) that received single agent carboplatin for different tumor types, a similar incidence of adverse events was seen in patients 65 years and older and in patients less than 65. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Because renal function is often decreased in the elderly, renal function should be considered in the selection of carboplatin injection dosage (see DOSAGE AND ADMINISTRATION )."],"clinical_studies_table":["
Overview of Pivotal Trials
NCIC SWOG
Number of patients randomized 447 342
Median age (years) 60 62
Dose of cisplatin 75 mg/m 2 100 mg/m 2
Dose of carboplatin 300 mg/m 2 300 mg/m 2
Dose of cyclophosphamide 600 mg/m 2 600 mg/m 2
Residual tumor < 2 cm (number of patients) 39% (174/447) 14% (49/342)
","
Clinical Response in Measurable Disease Patients
NCIC SWOG
Carboplatin (number of patients) 60% (48/80) 58% (48/83)
Cisplatin (number of patients) 58% (49/85) 43% (33/76)
95% CI of difference (Carboplatin-Cisplatin) (-13.9%, 18.6%) (-2.3%, 31.1%)
","
Pathologic Complete Response *
*114 Carboplatin and 109 Cisplatin patients did not undergo second look surgery in NCIC study.
90 Carboplatin and 106 Cisplatin patients did not undergo second look surgery in SWOG study.
NCIC SWOG
Carboplatin (number of patients) 11% (24/224) 10% (17/171)
Cisplatin (number of patients) 15% (33/223) 10% (17/171)
95% CI of difference (Carboplatin-Cisplatin) (-10.7%, 2.5%) (-6.9%, 6.9%)
","
Progression-Free Survival (PFS)
*Kalpan-Meier Estimates Unrelated deaths occurring in the absence of progression were counted as events (progression) in this analysis.
**Analysis adjusted for factors found to be of prognostic significance were consistent with unadjusted analysis.
NCIC SWOG
Median
Carboplatin 59 weeks 49 weeks
Cisplatin 61 weeks 47 weeks
2-year PFS *
Carboplatin 31% 21%
Cisplatin 31% 21%
95% CI of difference (Carboplatin-Cisplatin) (-9.3, 8.7) (-9, 9.4)
3-year PFS *
Carboplatin 19% 8%
Cisplatin 23% 14%
95% CI of difference (Carboplatin-Cisplatin) (-11.5, 4.5) (-14.1, 0.3)
Hazard Ratio** 1.10 1.02
95% CI (Carboplatin-Cisplatin) (0.89, 1.35) (0.81, 1.29)
","
Survival
*Kaplan-Meier Estimates
**Analysis adjusted for factors found to be of prognostic significance were consistent with unadjusted analysis.
NCIC SWOG
Median
Carboplatin 110 weeks 86 weeks
Cisplatin 99 weeks 79 weeks
2-year Survival *
Carboplatin 51.9% 40.2%
Cisplatin 48.4% 39.0%
95% CI of difference (Carboplatin-Cisplatin) (-6.2, 13.2) (-9.8, 12.2)
3-year Survival *
Carboplatin 34.6% 18.3%
Cisplatin 33.1% 24.9%
95% CI of difference (Carboplatin-Cisplatin) (-7.7, 10.7) (-15.9, 2.7)
Hazard Ratio *
95% CI 0.98 1.01
(Carboplatin–Cisplatin) (0.78, 1.23) (0.78, 1.30)
","
ADVERSE EXPERIENCES IN PATIENTS WITH OVARIAN CANCER NCIC STUDY
*Values are in percent of evaluable patients.
**ns = not significant, p>0.05
†May have been affected by cyclophosphamide dosage delivered
Carboplatin Arm Percent * Cisplatin Arm Percent * P-Values **
Bone Marrow
Thrombocytopenia <100,000/mm 3 70 29 <0.001
<50,000/mm 3 41 6 <0.001
Neutropenia <2,000 cells/mm 3 97 96 ns
<1,000 cells/mm 3 81 79 ns
Leukopenia <4,000 cells/mm 3 98 97 ns
<2,000 cells/mm 3 68 52 0.001
Anemia <11 g/dL 91 91 ns
<8 g/dL 18 12 ns
Infections 14 12 ns
Bleeding 10 4 ns
Transfusions 42 31 0.018
Gastrointestinal
Nausea and vomiting 93 98 0.010
Vomiting 84 97 <0.001
Other GI side effects 50 62 0.013
Neurologic
Peripheral neuropathies 16 42 <0.001
Ototoxicity 13 33 <0.001
Other sensory side effects 6 10 ns
Central neurotoxicity 28 40 0.009
Renal
Serum creatinine elevations 5 13 0.006
Blood urea elevations 17 31 <0.001
Hepatic
Bilirubin elevations 5 3 ns
SGOT elevations 17 13 ns
Alkaline phosphatase elevations - - -
Electrolytes loss
Sodium 10 20 0.005
Potassium 16 22 ns
Calcium 16 19 ns
Magnesium 63 88 <0.001
Other side effects
Pain 36 37 ns
Asthenia 40 33 ns
Cardiovascular 15 19 ns
Respiratory 8 9 ns
Allergic 12 9 ns
Genitourinary 10 10 ns
Alopecia † 50 62 0.017
Mucositis 10 9 ns
","
ADVERSE EXPERIENCES IN PATIENTS WITH OVARIAN CANCER SWOG STUDY
*Values are in percent of evaluable patients.
**ns = not significant, p>0.05
†May have been affected by cyclophosphamide dosage delivered
Carboplatin Arm Percent * Cisplatin Arm Percent * P-Values **
Bone Marrow
Thrombocytopenia <100,000/mm 3 59 35 <0.001
<50,000/mm 3 22 11 0.006
Neutropenia <2,000 cells/mm 3 95 97 ns
<1,000 cells/mm 3 84 78 ns
Leukopenia <4,000 cells/mm 3 97 97 ns
<2,000 cells/mm 3 76 67 ns
Anemia <11 g/dL 88 87 ns
<8 g/dL 8 24 <0.001
Infections 18 21 ns
Bleeding 6 4 ns
Transfusions 25 33 ns
Gastrointestinal
Nausea and vomiting 94 96 ns
Vomiting 82 91 0.007
Other GI side effects 40 48 ns
Neurologic
Peripheral neuropathies 13 28 0.001
Ototoxicity 12 30 <0.001
Other sensory side effects 4 6 ns
Central neurotoxicity 23 29 ns
Renal
Serum creatinine elevations 7 38 <0.001
Blood urea elevations - - -
Hepatic
Bilirubin elevations 5 3 ns
SGOT elevations 23 16 ns
Alkaline phosphatase elevations 29 20 ns
Electrolytes loss
Sodium - - -
Potassium - - -
Calcium - - -
Magnesium 58 77 <0.001
Other side effects
Pain 54 52 ns
Asthenia 43 46 ns
Cardiovascular 23 30 ns
Respiratory 12 11 ns
Allergic 10 11 ns
Genitourinary 11 13 ns
Alopecia † 43 57 0.009
Mucositis 6 11 ns
"],"adverse_reactions_table":["
ADVERSE EXPERIENCES IN PATIENTS WITH OVARIAN CANCER
*Use with Cyclophosphamide for Initial Treatment of Ovarian Cancer: Data are based on the experience of 393 patients with ovarian cancer (regardless of
baseline status) who received initial combination therapy with carboplatin and cyclophosphamide in two randomized controlled studies conducted by SWOG
and NCIC (see CLINICAL STUDIES).
Combination with cyclophosphamide as well as duration of treatment may be responsible for the differences that can be noted in the adverse experience table.
**Single Agent Use for the Secondary Treatment of Ovarian Cancer: Data are based on the experience of 553 patients with previously treated ovarian carcinoma
(regardless of baseline status) who received single agent carboplatin.
First Line Combination Therapy *Percent Second Line Single Agent Therapy **Percent
Bone Marrow
Thrombocytopenia<100,000/mm36662
<50,000/mm33335
Neutropenia<2,000 cells/mm39667
<1,000 cells/mm38221
Leukopenia<4,000 cells/mm39785
<2,000 cells/mm37126
Anemia<11 g/dL9090
<8g/dL1421
Infections165
Bleeding85
Transfusions3544
Gastrointestinal
Nausea and vomiting9392
Vomiting8381
Other GI side effects4621
Neurologic
Peripheral neuropathies156
Ototoxicity121
Other sensory side effects51
Central neurotoxicity265
Renal
Serum creatinine elevations610
Blood urea elevations1722
Hepatic
Bilirubin elevations55
SGOT elevations2019
Alkaline phosphatase elevations 2937
Electrolytes loss
Sodium1047
Potassium1628
Calcium1631
Magnesium6143
Other side effects
Pain4423
Asthenia4111
Cardiovascular196
Respiratory106
Allergic112
Genitourinary102
Alopecia492
Mucositis81
"],"spl_unclassified_section":["PREPARATION OF INTRAVENOUS SOLUTIONS Carboplatin injection is a premixed aqueous solution of 10 mg/mL carboplatin. Carboplatin injection can be further diluted to concentrations as low as 0.5 mg/mL with 5% Dextrose in Water (D 5 W) or 0.9% Sodium Chloride Injection USP. When prepared as directed, carboplatin injection is stable for 8 hours at room temperature (25°C). Since no antibacterial preservative is contained in the formulation, it is recommended that carboplatin injection be discarded 8 hours after dilution.","HANDLING AND DISPOSAL Caution should be exercised in handling and preparing carboplatin injection. Several guidelines on this subject have been published. 1-4 To minimize the risk of dermal exposure, always wear impervious gloves when handling vials containing carboplatin injection. If carboplatin injection contacts the skin, immediately wash the skin thoroughly with soap and water. If carboplatin injection contacts mucous membranes, the membranes should be flushed immediately and thoroughly with water. More information is available in the references listed below. REFERENCES NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004-165. OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling occupational exposure to hazardous drugs. OSHA, 1999. http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Health-Syst Pharm. 2006;63:1172-1193. Polovich M, White JM, Kelleher LO, eds. 2005. Chemotherapy and biotherapy guidelines and recommendations for practice. 2nd ed. Pittsburgh, PA: Oncology Nursing Society. Manufactured by: Teyro Labs Private Limited Plot No. A-9/1, SIPCOT Industrial Growth Centre Oragadam, Kanchipuram District, Tamil Nadu 601301, India (IND) Manufactured for: Apotex Corp. Weston Florida 33326 Revised: 01/2024","Patient Information CARBOplatin Injection Rx only Read this entire leaflet carefully. Keep it for future reference. This information will help you learn more about carboplatin injection. It cannot, however, cover all the possible warnings or side effects relating to carboplatin injection, and it does not list all of the benefits and risks of carboplatin injection. Your doctor should always be your first choice for detailed information about your medical condition and your treatment. Be sure to ask your doctor about any questions you may have. What is cancer? Under normal conditions, the cells in your body divide and grow in an orderly, controlled fashion. Cell division and growth are necessary for the human body to perform its functions and to repair itself. Cancer cells are different from normal cells because they are not able to control their own growth. The reasons for this abnormal growth are not yet fully understood. A tumor is a mass of unhealthy cells that are dividing and growing fast and in an uncontrolled way. When a tumor invades surrounding healthy body tissue it is known as a malignant tumor. A malignant tumor can spread (metastasize) from its original location to other parts of the body. What is carboplatin injection? Carboplatin injection is a medicine that is used to treat cancer of the ovaries. It acts by interfering with the division of rapidly multiplying cells, particularly cancer cells. Who should not take carboplatin injection? Treatment with carboplatin injection is not recommended if you: are allergic to carboplatin or other platinum-containing products; have a weakened blood-forming system (bone marrow depression) or significant bleeding; are pregnant, intend to become pregnant, or are breastfeeding a baby. How is carboplatin injection used? Only a professional experienced in the use of cancer drugs should give you this medication. Carboplatin injection is given by dripping the medicine slowly and directly into a vein (intravenous infusion) for 15 minutes or longer. Your doctor will determine the dose of carboplatin for you based on your weight, height, and kidney function. Carboplatin injection may be given alone or with other drugs. Treatment is usually repeated every four weeks for a number of cycles. Before and after carboplatin treatment, your doctor may give you medication to lessen the nausea and vomiting associated with this cancer treatment What should you tell your doctor before starting treatment with carboplatin injection? Discuss the benefits and risks of carboplatin injection with your doctor before beginning treatment. Be sure to inform your doctor: If you are allergic to carboplatin or other platinum-containing products; If you are or intend to become pregnant, since carboplatin may harm the developing fetus. It is important to use effective birth control while you are being treated with carboplatin injection. If you are breastfeeding, since nursing infants may be exposed to carboplatin in this way; If you are taking other medicines, including all prescription and non-prescription (over-the-counter) drugs, since carboplatin may affect the action of other medicines; If you have any other medical problems, especially chicken pox (including recent exposure to adults or children with chicken pox), shingles, hearing problems, infection, or kidney disease, since treatment with carboplatin increases the risk and severity of these conditions. What should I avoid while taking carboplatin injection? If you are pregnant or think you might be pregnant, or if you are breastfeeding, let your doctor know right away. Carboplatin may harm your developing fetus or breastfeeding baby. If you are a woman of childbearing age, you should use birth control to avoid getting pregnant while you are taking carboplatin. You should avoid contact with adults and children who have infections, and tell your doctor right away if you show signs of infection such as cough, fever, and/or chills. Also, while you are being treated with carboplatin or after you stop treatment, first check with your doctor before getting any immunizations (vaccinations). Avoid contact with adults or children who have received oral polio vaccine since they can pass the polio virus to you. What are the possible side effects of carboplatin injection? Carboplatin injection may cause unwanted effects, particularly because carboplatin interferes with the growth of normal cells as well as cancer cells. For example, the occurrence of another cancer (secondary malignancy) has been reported in patients receiving cancer chemotherapy with multiple drugs. It is not always possible to tell whether such effects are caused by carboplatin, another drug you may be taking, or your illness. Because some of these effects may be serious, you will need close medical supervision during treatment with carboplatin injection. The most serious side effects of carboplatin are: bleeding and reduced blood cells, including reduced red blood cells (anemia) and platelets (needed for proper blood clotting), which may be severe enough to require blood transfusion. You should tell your doctor right away if you notice any unusual bruising or bleeding, including black tarry stools or blood in the urine. infection – carboplatin can temporarily lower the number of white blood cells in your blood, increasing the risk of infection; life-threatening allergic reaction – during and after treatment the doctor or nurse will observe you carefully for signs of allergic reaction; kidney and liver problems; loss of hearing or ringing in the ears; Contact your doctor right away if you experience any of these effects, or notice effects that worry you or are troublesome. Of the less serious side effects associated with carboplatin treatment, the most common are nausea, vomiting, diarrhoea, loss of appetite, hair loss and numbness, tingling, burning, or pain in the hands and feet. This medicine was prescribed for your particular condition. It must be given under close medical supervision by a doctor trained in the use of drugs for the treatment of cancer. This summary does not include everything there is to know about carboplatin injection. Medicines are sometimes prescribed for purposes other than those listed in patient leaflets. If you have questions or concerns, or want more information about carboplatin injection, your physician and pharmacist have the complete prescribing information upon which this information is based. You may want to read it and discuss it with your doctor. Remember, no written summary can replace careful discussion with your doctor. Manufactured by: Teyro Labs Private Limited Plot No. A-9/1, SIPCOT Industrial Growth Centre Oragadam, Kanchipuram District, Tamil Nadu 601301, India (IND) Manufactured for: Apotex Corp. Weston Florida 33326 Revised: 01/2024"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION NOTE: Aluminium reacts with carboplatin causing precipitate formation and loss of potency, therefore, needles or intravenous sets containing aluminium parts that may come in contact with the drug must not be used for the preparation or administration of carboplatin injection. Single Agent Therapy Carboplatin injection, as a single agent, has been shown to be effective in patients with recurrent ovarian carcinoma at a dosage of 360 mg/m 2 IV on day 1 every 4 weeks (alternatively see Formula Dosing ). In general, however, single intermittent courses of carboplatin should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000. Combination Therapy with Cyclophosphamide In the chemotherapy of advanced ovarian cancer, an effective combination for previously untreated patients consists of: Carboplatin - 300 mg/m 2 IV on day 1 every 4 weeks for 6 cycles (alternatively see Formula Dosing ). Cyclophosphamide - 600 mg/m 2 IV on day 1 every 4 weeks for 6 cycles. For directions regarding the use and administration of cyclophosphamide please refer to its package insert (See CLINICAL STUDIES .) Intermittent courses of carboplatin in combination with cyclophosphamide should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000. Dose Adjustment Recommendations Pretreatment platelet count and performance status are important prognostic factors for severity of myelosuppression in previously treated patients. The suggested dose adjustments for single agent or combination therapy shown in the table below are modified from controlled trials in previously treated and untreated patients with ovarian carcinoma. Blood counts were done weekly, and the recommendations are based on the lowest post-treatment platelet or neutrophil value. Platelets Neutrophils Adjusted Dose Percentages apply to carboplatin injection as a single agent or to both carboplatin and cyclophosphamide in combination. In the controlled studies, dosages were also adjusted at a lower level (50% to 60%) for severe myelosuppression. Escalations above 125% were not recommended for these studies. ( From Prior Course ) > 100,000 > 2,000 125% 50 - 100,000 500 - 2,000 No Adjustment < 50,000 < 500 75% Carboplatin injection is usually administered by an infusion lasting 15 minutes or longer. No pre- or post-treatment hydration or forced diuresis is required. Patients with Impaired Kidney Function Patients with creatinine clearance values below 60 mL/min are at increased risk of severe bone marrow suppression. In renally-impaired patients who received single agent carboplatin therapy, the incidence of severe leukopenia, neutropenia, or thrombocytopenia has been about 25% when the dosage modifications in the table below have been used. Baseline Creatinine Clearance Recommended Dose on Day 1 41 - 59 mL/min 250 mg/m 2 16 - 40 mL/min 200 mg/m 2 The data available for patients with severely impaired kidney function (creatinine clearance below 15 mL/min) are too limited to permit a recommendation for treatment. These dosing recommendations apply to the initial course of treatment. Subsequent dosages should be adjusted according to the patient's tolerance based on the degree of bone marrow suppression. Formula Dosing Another approach for determining the initial dose of carboplatin injection is the use of mathematical formulae, which are based on a patient's pre-existing renal function or renal function and desired platelet nadir. Renal excretion is the major route of elimination for carboplatin (See CLINICAL PHARMACOLOGY .) The use of dosing formulae, as compared to empirical dose calculation based on body surface area, allows compensation for patient variations in pretreatment renal function that might otherwise result in either underdosing (in patients with above average renal function) or overdosing (in patients with impaired renal function). A simple formula for calculating dosage, based upon a patient's glomerular filtration rate (GFR in mL/min) and carboplatin injection target area under the concentration versus time curve (AUC in mg/mL•min), has been proposed by Calvert. In these studies, GFR was measured by 51 Cr-EDTA clearance. CALVERT FORMULA FOR CARBOPLATIN DOSING Total Dose (mg) = (target AUC) × (GFR + 25) Note: With the Calvert formula, the total dose of carboplatin is calculated in mg, not mg/m m 2 The target AUC of 4 mg/mL•min to 6 mg/mL•min using single agent carboplatin appears to provide the most appropriate dose range in previously treated patients. This study also showed a trend between the AUC of single agent carboplatin administered to previously treated patients and the likelihood of developing toxicity. % Actual Toxicity in Previously Treated Patients AUC ( mg / mL ∙ min ) Gr 3 or Gr 4 Thrombocytopenia Gr 3 or Gr 4 Leukopenia 4 to 5 16% 13% 6 to 7 33% 34% Geriatric Dosing Because renal function is often decreased in elderly patients, formula dosing of carboplatin injection based on estimates of GFR should be used in elderly patients to provide predictable plasma carboplatin injection AUCs and thereby minimize the risk of toxicity."],"spl_product_data_elements":["CARBOPLATIN CARBOPLATIN WATER CARBOPLATIN CARBOPLATIN"],"dosage_and_administration_table":["
PlateletsNeutrophilsAdjusted DosePercentages apply to carboplatin injection as a single agent or to both carboplatin and cyclophosphamide in combination. In the controlled studies, dosages were also adjusted at a lower level (50% to 60%) for severe myelosuppression. Escalations above 125% were not recommended for these studies.(From Prior Course)
> 100,000> 2,000125%
50 - 100,000500 - 2,000No Adjustment
< 50,000< 50075%
","
Baseline Creatinine ClearanceRecommended Dose on Day 1
41 - 59 mL/min250 mg/m 2
16 - 40 mL/min200 mg/m 2
","
CALVERT FORMULA FOR CARBOPLATIN DOSING
Total Dose (mg) = (target AUC) × (GFR + 25)
Note: With the Calvert formula, the total dose of carboplatin is calculated in mg,not mg/mm 2
","
% Actual Toxicityin PreviouslyTreated Patients
AUC (mg/mL∙min)Gr 3 or Gr 4 ThrombocytopeniaGr 3 or Gr 4 Leukopenia
4 to 516%13%
6 to 733%34%
"],"package_label_principal_display_panel":["PACKAGE LABEL-PRINCIPAL DISPLAY PANEL Carboplatin Injection 50 mg/5 mL - NDC 60505-6282-1 Container Label Carboplatin Injection 50 mg/5 mL - NDC 60505-6282-1 Carton Label Carboplatin Injection 150 mg/15 mL - NDC 60505-6282-3 Container Label Carboplatin Injection 150 mg/15 mL - NDC 60505-6282-3 Carton Label Carboplatin Injection 450 mg/45 mL - NDC 60505-6282-6 Container Label Carboplatin Injection 450 mg/45 mL - NDC 60505-6282-6 Carton Label Carboplatin Injection 600 mg/60 mL - NDC 60505-6282-7 Container Label Carboplatin Injection 600 mg/60 mL - NDC 60505-6282-7 Carton Label Teyro-carton-label-5-ml Teyro-vial-label-5-ml Teyro-carton-15-ml Teyro-vial-label-15-ml Teyro-carton-label-45-ml Teyro-vial-45-ml Teyro-carton-label-60-ml Teyro-carton-label-60-ml"]},"tags":[{"label":"Platinum-based Drug","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"L01XA02","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Solution","category":"form"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Breast cancer","category":"indication"},{"label":"Malignant tumor of ovary","category":"indication"},{"label":"MYLAN SEIYAKU Ltd","category":"company"},{"label":"Approved 1980s","category":"decade"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Cross-Linking Reagents","category":"pharmacology"},{"label":"Indicators and Reagents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":["Carboplatin injection should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate treatment facilities are readily available. Bone marrow suppression is dose related and may be severe, resulting in infection and/or bleeding. Anemia may be cumulative and may require transfusion support. Vomiting is another frequent drug related side effect. Anaphylactic-like reactions to carboplatin have been reported and may occur within minutes of carboplatin injection administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms."],"safetySignals":[{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"8005 reports"},{"date":"","signal":"NEUTROPENIA","source":"FDA FAERS","actionTaken":"7121 reports"},{"date":"","signal":"ANAEMIA","source":"FDA FAERS","actionTaken":"6913 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"6799 reports"},{"date":"","signal":"FEBRILE NEUTROPENIA","source":"FDA FAERS","actionTaken":"6306 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"5945 reports"},{"date":"","signal":"DISEASE PROGRESSION","source":"FDA FAERS","actionTaken":"5839 reports"},{"date":"","signal":"MALIGNANT NEOPLASM PROGRESSION","source":"FDA FAERS","actionTaken":"5706 reports"},{"date":"","signal":"THROMBOCYTOPENIA","source":"FDA FAERS","actionTaken":"5671 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"5209 reports"}],"commonSideEffects":[{"effect":"DIARRHOEA","drugRate":"67.2%","placeboRate":"","totalAtRisk":5067,"totalAffected":3406,"trialsReporting":3},{"effect":"NAUSEA","drugRate":"46.5%","placeboRate":"","totalAtRisk":5067,"totalAffected":2357,"trialsReporting":3},{"effect":"ALOPECIA","drugRate":"41.2%","placeboRate":"","totalAtRisk":5067,"totalAffected":2089,"trialsReporting":3},{"effect":"FATIGUE","drugRate":"37.7%","placeboRate":"","totalAtRisk":5067,"totalAffected":1912,"trialsReporting":3},{"effect":"RASH","drugRate":"30.4%","placeboRate":"","totalAtRisk":5067,"totalAffected":1541,"trialsReporting":3},{"effect":"Fatigue","drugRate":"43.7%","placeboRate":"","totalAtRisk":3391,"totalAffected":1481,"trialsReporting":5},{"effect":"ARTHRALGIA","drugRate":"27.5%","placeboRate":"","totalAtRisk":5067,"totalAffected":1391,"trialsReporting":3},{"effect":"Nausea","drugRate":"32.8%","placeboRate":"","totalAtRisk":4038,"totalAffected":1326,"trialsReporting":6},{"effect":"Alopecia","drugRate":"43.2%","placeboRate":"","totalAtRisk":2880,"totalAffected":1243,"trialsReporting":4},{"effect":"ANAEMIA","drugRate":"23.2%","placeboRate":"","totalAtRisk":5067,"totalAffected":1177,"trialsReporting":3},{"effect":"VOMITING","drugRate":"23.1%","placeboRate":"","totalAtRisk":5067,"totalAffected":1172,"trialsReporting":3},{"effect":"CONSTIPATION","drugRate":"20.5%","placeboRate":"","totalAtRisk":5067,"totalAffected":1038,"trialsReporting":3},{"effect":"NEUTROPENIA","drugRate":"20.1%","placeboRate":"","totalAtRisk":5067,"totalAffected":1020,"trialsReporting":3},{"effect":"MYALGIA","drugRate":"19.2%","placeboRate":"","totalAtRisk":5067,"totalAffected":975,"trialsReporting":3},{"effect":"STOMATITIS","drugRate":"19.1%","placeboRate":"","totalAtRisk":5067,"totalAffected":967,"trialsReporting":3},{"effect":"Hemoglobin","drugRate":"81.5%","placeboRate":"","totalAtRisk":1158,"totalAffected":944,"trialsReporting":2},{"effect":"DECREASED APPETITE","drugRate":"18.0%","placeboRate":"","totalAtRisk":5067,"totalAffected":912,"trialsReporting":3},{"effect":"Leukocytes","drugRate":"78.1%","placeboRate":"","totalAtRisk":1158,"totalAffected":904,"trialsReporting":2},{"effect":"EPISTAXIS","drugRate":"17.5%","placeboRate":"","totalAtRisk":5067,"totalAffected":888,"trialsReporting":3},{"effect":"HEADACHE","drugRate":"17.4%","placeboRate":"","totalAtRisk":5067,"totalAffected":880,"trialsReporting":3},{"effect":"MUCOSAL INFLAMMATION","drugRate":"16.3%","placeboRate":"","totalAtRisk":5067,"totalAffected":827,"trialsReporting":3},{"effect":"ASTHENIA","drugRate":"15.7%","placeboRate":"","totalAtRisk":5067,"totalAffected":795,"trialsReporting":3},{"effect":"PYREXIA","drugRate":"15.5%","placeboRate":"","totalAtRisk":5067,"totalAffected":786,"trialsReporting":3},{"effect":"Constipation","drugRate":"23.1%","placeboRate":"","totalAtRisk":3391,"totalAffected":784,"trialsReporting":5},{"effect":"PERIPHERAL SENSORY NEUROPATHY","drugRate":"15.2%","placeboRate":"","totalAtRisk":5067,"totalAffected":769,"trialsReporting":3},{"effect":"PRURITUS","drugRate":"14.7%","placeboRate":"","totalAtRisk":5067,"totalAffected":745,"trialsReporting":3},{"effect":"HOT FLUSH","drugRate":"14.6%","placeboRate":"","totalAtRisk":5067,"totalAffected":738,"trialsReporting":3},{"effect":"Vomiting","drugRate":"17.4%","placeboRate":"","totalAtRisk":4038,"totalAffected":702,"trialsReporting":6},{"effect":"NEUROPATHY PERIPHERAL","drugRate":"13.8%","placeboRate":"","totalAtRisk":5067,"totalAffected":701,"trialsReporting":3},{"effect":"COUGH","drugRate":"13.8%","placeboRate":"","totalAtRisk":5067,"totalAffected":698,"trialsReporting":3},{"effect":"INSOMNIA","drugRate":"13.2%","placeboRate":"","totalAtRisk":5067,"totalAffected":669,"trialsReporting":3},{"effect":"NAIL DISORDER","drugRate":"14.5%","placeboRate":"","totalAtRisk":4425,"totalAffected":642,"trialsReporting":2},{"effect":"Platelets","drugRate":"53.1%","placeboRate":"","totalAtRisk":1158,"totalAffected":615,"trialsReporting":2},{"effect":"ABDOMINAL PAIN","drugRate":"12.1%","placeboRate":"","totalAtRisk":5067,"totalAffected":613,"trialsReporting":3},{"effect":"DRY SKIN","drugRate":"12.1%","placeboRate":"","totalAtRisk":5067,"totalAffected":612,"trialsReporting":3},{"effect":"OEDEMA PERIPHERAL","drugRate":"11.6%","placeboRate":"","totalAtRisk":5067,"totalAffected":590,"trialsReporting":3},{"effect":"DYSPEPSIA","drugRate":"10.8%","placeboRate":"","totalAtRisk":5067,"totalAffected":546,"trialsReporting":3},{"effect":"DYSPNOEA","drugRate":"10.2%","placeboRate":"","totalAtRisk":5067,"totalAffected":518,"trialsReporting":3},{"effect":"Hypertension","drugRate":"18.2%","placeboRate":"","totalAtRisk":2829,"totalAffected":514,"trialsReporting":4},{"effect":"NEUTROPHIL COUNT DECREASED","drugRate":"16.7%","placeboRate":"","totalAtRisk":3006,"totalAffected":502,"trialsReporting":2},{"effect":"NASOPHARYNGITIS","drugRate":"9.7%","placeboRate":"","totalAtRisk":5067,"totalAffected":492,"trialsReporting":3},{"effect":"Neutrophils","drugRate":"94.7%","placeboRate":"","totalAtRisk":511,"totalAffected":484,"trialsReporting":1},{"effect":"DYSGEUSIA","drugRate":"15.8%","placeboRate":"","totalAtRisk":3006,"totalAffected":475,"trialsReporting":2},{"effect":"Hair loss/alopecia (scalp or body)","drugRate":"73.1%","placeboRate":"","totalAtRisk":647,"totalAffected":473,"trialsReporting":1},{"effect":"LEUKOPENIA","drugRate":"9.1%","placeboRate":"","totalAtRisk":5067,"totalAffected":463,"trialsReporting":3},{"effect":"Anorexia","drugRate":"22.9%","placeboRate":"","totalAtRisk":1988,"totalAffected":455,"trialsReporting":2},{"effect":"PAIN IN EXTREMITY","drugRate":"8.9%","placeboRate":"","totalAtRisk":5067,"totalAffected":453,"trialsReporting":3},{"effect":"DIZZINESS","drugRate":"8.9%","placeboRate":"","totalAtRisk":5067,"totalAffected":452,"trialsReporting":3},{"effect":"PARAESTHESIA","drugRate":"8.9%","placeboRate":"","totalAtRisk":5067,"totalAffected":451,"trialsReporting":3},{"effect":"Rash","drugRate":"23.5%","placeboRate":"","totalAtRisk":1914,"totalAffected":450,"trialsReporting":4}],"contraindications":["History of severe allergic reactions to cisplatin or other platinum-containing compounds","Severe bone marrow depression","Significant bleeding"],"specialPopulations":{"Pregnancy":"See WARNINGS.","Geriatric use":"Of the 789 patients in initial treatment combination therapy studies (NCIC and SWOG), 395patients were treated with carboplatin, USP in combination with cyclophosphamide. Of these,141 were over 65 years of age and 22 were 75 years or older. In these trials, age was not aprognostic factor for survival. In terms of safety, elderly patients treated with carboplatin USPwere more likely to develop severe thrombocytopenia than younger patients.","Paediatric use":"Safety and effectiveness in pediatric patients have not been established (see WARNINGS; audiologic toxicity)."}},"trials":[],"aliases":[],"company":"MYLAN SEIYAKU Ltd","patents":[{"applNo":"N219921","source":"FDA Orange Book","status":"Active","expires":"Apr 1, 2045","useCode":"","territory":"US","drugProduct":true,"patentNumber":"12427104","drugSubstance":false}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Carboplatin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:35:01.799439+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T23:35:01.799363+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Carboplatin","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-19T23:35:08.836536+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"Haiku strategic summary","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T07:55:26.469827+00:00"},"mechanism":{"url":"","method":"ai_extraction","source":"FDA Label + Haiku","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T08:35:15.775706+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:35:07.503760+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:35:00.639302+00:00"},"pharmacokinetics":{"url":"","method":"ai_extraction","source":"FDA Label + Haiku","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T08:35:15.775733+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Carboplatin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:35:07.789703+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:34:59.567722+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:34:59.567742+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"Carboplatin injection should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate treatment facilities are readily available. Bone marrow suppression is dose related and may be severe, resulting in infection and/or bleeding. Anemia may be cumulative and may require transfusion support. Vomiting is another frequent drug related side effect. Anaphyl","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:34:59.567747+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:35:09.320034+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: DNA inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:35:08.836474+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1351/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:35:08.486064+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + Haiku","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:55:26.469806+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA077861","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:34:59.567750+00:00"}},"allNames":"paraplatin","offLabel":[],"synonyms":["paraplatin","carboplatin"],"timeline":[{"date":"1989-03-03","type":"positive","source":"DrugCentral","milestone":"FDA approval"},{"date":"2004-01-15","type":"positive","source":"FDA Orange Book","milestone":"Paraplatin approved — 600MG/60ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**"},{"date":"2007-04-24","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 13 manufacturers approved"},{"date":"2021-08-25","type":"positive","source":"DrugCentral","milestone":"PMDA approval (MYLAN SEIYAKU Ltd)"}],"aiSummary":"Carboplatin is indicated for initial treatment of advanced ovarian carcinoma in combination with other chemotherapeutic agents and for palliative treatment of recurrent ovarian carcinoma after prior chemotherapy. It demonstrates equivalent efficacy to cisplatin with a more favorable aquation profile, though patients with progressive disease during prior cisplatin therapy may have decreased response rates. The drug exhibits linear pharmacokinetics with biphasic plasma decay and primarily renal elimination. Carboplatin is contraindicated in patients with severe allergic reactions to platinum compounds, severe bone marrow depression, or significant bleeding.","brandName":"Paraplatin","ecosystem":[{"indication":"Breast cancer","otherDrugs":[],"globalPrevalence":1800000},{"indication":"Malignant tumor of ovary","otherDrugs":[{"name":"altretamine","slug":"altretamine","company":"Eisai Inc"},{"name":"cisplatin","slug":"cisplatin","company":"Hq Spclt Pharma"},{"name":"doxorubicin","slug":"doxorubicin","company":""},{"name":"gemcitabine","slug":"gemcitabine","company":"Lilly"}],"globalPrevalence":null}],"mechanism":{"target":"DNA","novelty":"Follow-on","modality":"Small molecule chemotherapy","drugClass":"Platinum-containing alkylating agent","explanation":"Carboplatin, like cisplatin, produces predominantly interstrand DNA cross-links rather than DNA-protein cross-links through a cell-cycle nonspecific mechanism. The aquation of carboplatin, which produces the active species, occurs at a slower rate than cisplatin. Despite differences in aquation rates, both carboplatin and cisplatin induce equal numbers of drug-DNA cross-links, causing equivalent lesions and biological effects, with potency differences directly related to aquation rate differences.","oneSentence":"Carboplatin produces predominantly interstrand DNA cross-links in a cell-cycle nonspecific manner.","technicalDetail":"Paraplatin exerts its cytotoxic effects through the formation of platinum-DNA adducts, specifically platinum-DNA intrastrand crosslinks, which interfere with DNA replication and transcription, leading to cell cycle arrest and apoptosis."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Carboplatin","title":"Carboplatin","extract":"Carboplatin, sold under the brand name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It is administered by injection into a vein sometimes via a port.","wiki_history":"==History==\nCarboplatin, a cisplatin analogue, was developed by Bristol Myers Squibb and the Institute of Cancer Research in order to reduce the toxicity of cisplatin. It gained U.S. Food and Drug Administration (FDA) approval for carboplatin, under the brand name Paraplatin, in March 1989. Starting in October 2004, generic versions of the drug became available."},"commercial":{"launchDate":"1989","_launchSource":"DrugCentral (FDA 1989-03-03, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4133","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=Carboplatin","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Carboplatin","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Carboplatin","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T01:56:12.342150","_validation":{"fieldsValidated":5,"lastValidatedAt":"2026-04-20T08:35:21.079866+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"cisplatin","drugSlug":"cisplatin","fdaApproval":"1978-12-19","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"oxaliplatin","drugSlug":"oxaliplatin","fdaApproval":"2002-08-09","genericCount":21,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"carboplatin","indications":{"approved":[{"name":"Breast cancer","source":"DrugCentral","snomedId":254837009,"regulator":"FDA","usPrevalence":null,"globalPrevalence":1800000,"prevalenceMethod":"curated","prevalenceSource":"IARC GLOBOCAN, 2022"},{"name":"Malignant tumor of ovary","source":"DrugCentral","snomedId":363443007,"regulator":"FDA"}],"offLabel":[{"name":"Acute myeloid leukemia, disease","source":"DrugCentral","drugName":"Carboplatin","evidenceCount":109,"evidenceLevel":"strong"},{"name":"Endometrial carcinoma","source":"DrugCentral","drugName":"Carboplatin","evidenceCount":710,"evidenceLevel":"strong"},{"name":"Ewing's sarcoma","source":"DrugCentral","drugName":"Carboplatin","evidenceCount":53,"evidenceLevel":"strong"},{"name":"Malignant tumor of cervix","source":"DrugCentral","drugName":"Carboplatin","evidenceCount":206,"evidenceLevel":"strong"},{"name":"Malignant tumor of head and/or neck","source":"DrugCentral","drugName":"Carboplatin","evidenceCount":510964,"evidenceLevel":"strong"},{"name":"Malignant tumor of testis","source":"DrugCentral","drugName":"Carboplatin","evidenceCount":574,"evidenceLevel":"strong"},{"name":"Malignant tumor of urinary bladder","source":"DrugCentral","drugName":"Carboplatin","evidenceCount":511,"evidenceLevel":"strong"},{"name":"Metastatic Breast Carcinoma","source":"DrugCentral","drugName":"Carboplatin","evidenceCount":671,"evidenceLevel":"strong"},{"name":"Neuroendocrine Prostate Carcinoma","source":"DrugCentral","drugName":"Carboplatin","evidenceCount":34,"evidenceLevel":"moderate"},{"name":"Non-small cell lung cancer","source":"DrugCentral","drugName":"Carboplatin","evidenceCount":4202,"evidenceLevel":"strong"},{"name":"Progressive Diffuse Large B-Cell Lymphoma","source":"DrugCentral","drugName":"Carboplatin"},{"name":"Refractory Osteosarcoma","source":"DrugCentral","drugName":"Carboplatin"},{"name":"Seminoma of testis","source":"DrugCentral","drugName":"Carboplatin"},{"name":"Small cell carcinoma of lung","source":"DrugCentral","drugName":"Carboplatin"}],"pipeline":[]},"currentOwner":"Avyxa Holdings","drugCategory":"established","labelChanges":[],"relatedDrugs":[{"drugId":"cisplatin","brandName":"cisplatin","genericName":"cisplatin","approvalYear":"1978","relationship":"same-class"},{"drugId":"oxaliplatin","brandName":"oxaliplatin","genericName":"oxaliplatin","approvalYear":"2002","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03907475","phase":"PHASE2","title":"Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-16","conditions":["Locally Advanced Malignant Solid Neoplasm","Metastatic Malignant Solid Neoplasm"],"enrollment":115,"completionDate":"2026-06-01"},{"nctId":"NCT07155174","phase":"PHASE2","title":"A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-11-25","conditions":["Small Cell Lung Cancer"],"enrollment":180,"completionDate":"2031-09"},{"nctId":"NCT01167712","phase":"PHASE3","title":"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-09-27","conditions":["Fallopian Tube Endometrioid Adenocarcinoma","Fallopian Tube Mucinous Adenocarcinoma","Fallopian Tube Transitional Cell Carcinoma","Ovarian Brenner Tumor","Ovarian Clear Cell Adenocarcinofibroma","Ovarian Endometrioid Adenocarcinoma","Ovarian Mucinous Adenocarcinoma","Ovarian Seromucinous Carcinoma","Ovarian Serous Adenocarcinoma","Ovarian Transitional Cell Carcinoma","Ovarian Undifferentiated Carcinoma","Primary Peritoneal Serous Adenocarcinoma","Stage IIA Fallopian Tube Cancer AJCC v6 and v7","Stage IIA Ovarian Cancer AJCC V6 and v7","Stage IIB Fallopian Tube Cancer AJCC v6 and v7","Stage IIB Ovarian Cancer AJCC v6 and v7","Stage IIC Fallopian Tube Cancer AJCC v6 and v7","Stage IIC Ovarian Cancer AJCC v6 and v7","Stage IIIA Fallopian Tube Cancer AJCC v7","Stage IIIA Ovarian Cancer AJCC v6 and v7","Stage IIIA Primary Peritoneal Cancer AJCC v7","Stage IIIB Fallopian Tube Cancer AJCC v7","Stage IIIB Ovarian Cancer AJCC v6 and v7","Stage IIIB Primary Peritoneal Cancer AJCC v7","Stage IIIC Fallopian Tube Cancer AJCC v7","Stage IIIC Ovarian Cancer AJCC v6 and v7","Stage IIIC Primary Peritoneal Cancer AJCC v7","Stage IV Fallopian Tube Cancer AJCC v6 and v7","Stage IV Ovarian Cancer AJCC v6 and v7","Stage IV Primary Peritoneal Cancer AJCC v7"],"enrollment":692,"completionDate":"2026-07-02"},{"nctId":"NCT06225596","phase":"PHASE2,PHASE3","title":"Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)","status":"RECRUITING","sponsor":"BicycleTx Limited","startDate":"2024-01-24","conditions":["Metastatic Urothelial Cancer"],"enrollment":956,"completionDate":"2030-12"},{"nctId":"NCT07020065","phase":"PHASE2","title":"Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%","status":"NOT_YET_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2026-05","conditions":["Metastatic NSCLC - Non-Small Cell Lung Cancer"],"enrollment":156,"completionDate":"2030-03"},{"nctId":"NCT04166409","phase":"PHASE3","title":"A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-01-31","conditions":["Low Grade Astrocytoma","Low Grade Glioma","Metastatic Low Grade Astrocytoma","Metastatic Low Grade Glioma","WHO Grade 1 Glioma","WHO Grade 2 Glioma"],"enrollment":170,"completionDate":"2030-12-31"},{"nctId":"NCT06841354","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-16","conditions":["Triple Negative Breast Neoplasms"],"enrollment":1000,"completionDate":"2030-05-18"},{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":["Breast Neoplasms","Triple Negative Breast Neoplasms","HR Low-Positive/HER2-Negative Breast Neoplasms"],"enrollment":2400,"completionDate":"2034-12-29"},{"nctId":"NCT07024784","phase":"PHASE2","title":"A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-07-30","conditions":["Gynecologic Cancers","Platinum-Sensitive Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Cancer (PSOC)"],"enrollment":377,"completionDate":"2028-02"},{"nctId":"NCT07055581","phase":"PHASE2","title":"Durvalumab as Consolidation for Patients LS-SCLC","status":"RECRUITING","sponsor":"Qian Chu","startDate":"2026-02-24","conditions":["Small Cell Lung Cancer Limited Stage"],"enrollment":100,"completionDate":"2029-07-31"},{"nctId":"NCT06305754","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-11","conditions":["Non-small Cell Lung Cancer (NSCLC)"],"enrollment":520,"completionDate":"2030-06-14"},{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":["Ganglioneuroblastoma, Nodular","Neuroblastoma"],"enrollment":478,"completionDate":"2029-12-31"},{"nctId":"NCT05058651","phase":"PHASE2,PHASE3","title":"Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-28","conditions":["Advanced Extrapulmonary Neuroendocrine Carcinoma","Metastatic Extrapulmonary Neuroendocrine Carcinoma","Recurrent Extrapulmonary Neuroendocrine Carcinoma","Unresectable Extrapulmonary Neuroendocrine Carcinoma"],"enrollment":189,"completionDate":"2028-10-01"},{"nctId":"NCT03606967","phase":"PHASE2","title":"Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-13","conditions":["Anatomic Stage IV Breast Cancer AJCC v8","Invasive Breast Carcinoma","Metastatic Triple-Negative Breast Carcinoma"],"enrollment":70,"completionDate":"2026-12-30"},{"nctId":"NCT06029270","phase":"PHASE2","title":"Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-15","conditions":["Metastatic Nasopharyngeal Carcinoma","Recurrent Nasopharyngeal Carcinoma","Stage IV Nasopharyngeal Carcinoma AJCC v8"],"enrollment":156,"completionDate":"2029-04-30"},{"nctId":"NCT05198830","phase":"PHASE2","title":"Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-12-15","conditions":["Lung Adenocarcinoma","Lung Large Cell Carcinoma","Lung Non-Squamous Non-Small Cell Carcinoma","Stage III Lung Cancer AJCC v8"],"enrollment":42,"completionDate":"2027-06-30"},{"nctId":"NCT07198074","phase":"PHASE3","title":"Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-01-27","conditions":["Advanced Endometrial Carcinoma","Recurrent Endometrial Carcinoma"],"enrollment":255,"completionDate":"2028-07-01"},{"nctId":"NCT02535312","phase":"PHASE1,PHASE2","title":"Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-03-08","conditions":["Advanced Malignant Solid Neoplasm","Advanced Peritoneal Malignant Mesothelioma","Advanced Pleural Malignant Mesothelioma","Recurrent Peritoneal Malignant Mesothelioma","Recurrent Pleural Malignant Mesothelioma","Refractory Malignant Solid Neoplasm","Unresectable Solid Neoplasm"],"enrollment":30,"completionDate":"2026-10-15"},{"nctId":"NCT06422143","phase":"PHASE3","title":"Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-10","conditions":["Non-small Cell Lung Cancer","NSCLC"],"enrollment":851,"completionDate":"2031-02-12"},{"nctId":"NCT03387553","phase":"EARLY_PHASE1","title":"HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-06-06","conditions":["Breast Cancer","Breast Cancer Female","Breast Cancer, Male","Invasive Breast Cancer","HER2-positive Breast Cancer","HER2 Positive Breast Carcinoma","Stage II Breast Cancer","Stage III Breast Cancer"],"enrollment":31,"completionDate":"2026-07-30"},{"nctId":"NCT04444921","phase":"PHASE3","title":"EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-11-17","conditions":["Anal Basaloid Carcinoma","Anal Canal Cloacogenic Carcinoma","Metastatic Anal Squamous Cell Carcinoma","Recurrent Anal Squamous Cell Carcinoma","Stage III Anal Cancer AJCC v8","Stage IV Anal Cancer AJCC v8","Unresectable Anal Squamous Cell Carcinoma"],"enrollment":205,"completionDate":"2027-03-31"},{"nctId":"NCT01366144","phase":"PHASE1","title":"Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-06-20","conditions":["Breast Carcinoma","Carcinoma of Unknown Primary","Endometrial Carcinoma","Esophageal Carcinoma","Liver Failure","Lung Carcinoma","Malignant Head and Neck Neoplasm","Malignant Testicular Neoplasm","Melanoma","Metastatic Malignant Solid Neoplasm","Ovarian Carcinoma","Renal Failure","Unresectable Malignant Neoplasm","Urothelial Carcinoma"],"enrollment":94,"completionDate":"2027-03-03"},{"nctId":"NCT03289910","phase":"PHASE2","title":"Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-24","conditions":["Acute Myeloid Leukemia","Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","Atypical Chronic Myeloid Leukemia","Chronic Myelomonocytic Leukemia","Essential Thrombocythemia","Myelodysplastic/Myeloproliferative Neoplasm","Myelofibrosis","Polycythemia Vera","Recurrent Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia"],"enrollment":25,"completionDate":"2026-12-18"},{"nctId":"NCT05017012","phase":"PHASE1","title":"A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-21","conditions":["Advanced or Metastatic Solid Tumors"],"enrollment":72,"completionDate":"2026-05-19"},{"nctId":"NCT03997370","phase":"PHASE1","title":"Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2020-01-15","conditions":["Malignant Solid Neoplasm"],"enrollment":318,"completionDate":"2028-02-06"},{"nctId":"NCT07495124","phase":"PHASE2","title":"IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence","status":"NOT_YET_RECRUITING","sponsor":"University of Washington","startDate":"2026-04-01","conditions":["Fallopian Tube Carcinoma","Ovarian Carcinoma","Primary Peritoneal Carcinoma"],"enrollment":26,"completionDate":"2028-09-30"},{"nctId":"NCT06953323","phase":"PHASE1,PHASE2","title":"A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors","status":"RECRUITING","sponsor":"Wigen Biomedicine Technology (Shanghai) Co., Ltd.","startDate":"2025-07-10","conditions":["Advanced Solid Tumor"],"enrollment":86,"completionDate":"2029-12-30"},{"nctId":"NCT04671667","phase":"PHASE2","title":"Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-27","conditions":["Recurrent Head and Neck Squamous Cell Carcinoma","Recurrent Hypopharyngeal Squamous Cell Carcinoma","Recurrent Laryngeal Squamous Cell Carcinoma","Recurrent Oral Cavity Squamous Cell Carcinoma","Recurrent Oropharyngeal Squamous Cell Carcinoma"],"enrollment":188,"completionDate":"2029-06-30"},{"nctId":"NCT06439225","phase":"PHASE3","title":"Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2024-12-30","conditions":["Metastatic Castration-resistant Prostate Cancer","Metastatic Prostate Cancer"],"enrollment":236,"completionDate":"2030-03-31"},{"nctId":"NCT07498907","phase":"PHASE2","title":"Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Peking University First Hospital","startDate":"2026-05-01","conditions":["Upper Tract Urothelial Carcinoma"],"enrollment":192,"completionDate":"2034-03-01"},{"nctId":"NCT07195734","phase":"PHASE2","title":"Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-09","conditions":["Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Locally Recurrent Head and Neck Squamous Cell Carcinoma","Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma","Locally Recurrent Laryngeal Squamous Cell Carcinoma","Locally Recurrent Oral Cavity Squamous Cell Carcinoma","Locally Recurrent Oropharyngeal Squamous Cell Carcinoma","Stage II Laryngeal Cancer AJCC v8","Stage II Lip and Oral Cavity Cancer AJCC v8","Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage III Laryngeal Cancer AJCC v8","Stage III Lip and Oral Cavity Cancer AJCC v8","Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage IVA Laryngeal Cancer AJCC v8","Stage IVA Lip and Oral Cavity Cancer AJCC v8","Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage IVB Laryngeal Cancer AJCC v8","Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8"],"enrollment":180,"completionDate":"2033-02-01"},{"nctId":"NCT01386385","phase":"PHASE1,PHASE2","title":"Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-06-20","conditions":["Lung Adenocarcinoma","Lung Adenocarcinoma, Mixed Subtype","Lung Large Cell Carcinoma","Lung Squamous Cell Carcinoma","Minimally Invasive Lung Adenocarcinoma","Stage III Lung Non-Small Cell Cancer AJCC v7","Stage IIIA Lung Non-Small Cell Cancer AJCC v7","Stage IIIB Lung Non-Small Cell Cancer AJCC v7"],"enrollment":53,"completionDate":"2026-12-31"},{"nctId":"NCT03914612","phase":"PHASE3","title":"Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-22","conditions":["Endometrial Clear Cell Adenocarcinoma","Endometrial Dedifferentiated Carcinoma","Endometrial Endometrioid Adenocarcinoma","Endometrial Mixed Cell Adenocarcinoma","Endometrial Serous Adenocarcinoma","Endometrial Undifferentiated Carcinoma","Recurrent Endometrial Adenocarcinoma","Recurrent Endometrial Carcinoma","Recurrent Endometrial Clear Cell Adenocarcinoma","Recurrent Endometrial Dedifferentiated Carcinoma","Recurrent Endometrial Endometrioid Adenocarcinoma","Recurrent Endometrial Mixed Cell Adenocarcinoma","Recurrent Endometrial Serous Adenocarcinoma","Recurrent Endometrial Undifferentiated Carcinoma","Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8","Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8"],"enrollment":813,"completionDate":"2026-09-26"},{"nctId":"NCT03604991","phase":"PHASE2,PHASE3","title":"Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-05-03","conditions":["Clinical Stage II Esophageal Adenocarcinoma AJCC v8","Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage III Esophageal Adenocarcinoma AJCC v8","Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8","Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8","Esophageal Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma"],"enrollment":278,"completionDate":"2026-12-31"},{"nctId":"NCT06561685","phase":"PHASE1","title":"A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-09-19","conditions":["Metastatic Solid Tumor","Advanced Solid Tumor","Non-small Cell Lung Cancer","SMARCA4-Deficient Tumor"],"enrollment":340,"completionDate":"2027-10"},{"nctId":"NCT06843447","phase":"PHASE1,PHASE2","title":"A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-15","conditions":["Ovarian Cancer Recurrent"],"enrollment":280,"completionDate":"2029-03-27"},{"nctId":"NCT05256225","phase":"PHASE3","title":"Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-16","conditions":["Endometrial Carcinoma","Endometrial Clear Cell Adenocarcinoma","Endometrial Dedifferentiated Carcinoma","Endometrial Endometrioid Adenocarcinoma","Endometrial Mixed Cell Adenocarcinoma","Endometrial Serous Adenocarcinoma","Endometrial Undifferentiated Carcinoma","Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor"],"enrollment":360,"completionDate":"2027-10-31"},{"nctId":"NCT07043725","phase":"PHASE3","title":"A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-09-15","conditions":["HER2-positive Breast Cancer"],"enrollment":544,"completionDate":"2029-09"},{"nctId":"NCT07061977","phase":"PHASE3","title":"Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-11-05","conditions":["Locally Advanced Cervical Adenocarcinoma","Locally Advanced Cervical Adenosquamous Carcinoma","Locally Advanced Cervical Squamous Cell Carcinoma","Stage IIIA Cervical Cancer FIGO 2018","Stage IIIB Cervical Cancer FIGO 2018","Stage IIIC1 Cervical Cancer FIGO 2018","Stage IIIC2 Cervical Cancer FIGO 2018","Stage IVA Cervical Cancer FIGO 2018"],"enrollment":336,"completionDate":"2030-12-31"},{"nctId":"NCT06627647","phase":"PHASE3","title":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-11-27","conditions":["Non-squamous Non-small Cell Lung Cancer"],"enrollment":878,"completionDate":"2030-03-25"},{"nctId":"NCT04092283","phase":"PHASE3","title":"Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-04-29","conditions":["Recurrent Lung Non-Small Cell Carcinoma","Stage III Lung Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIB Lung Cancer AJCC v8","Stage IIIC Lung Cancer AJCC v8","Unresectable Lung Non-Small Cell Carcinoma"],"enrollment":660,"completionDate":"2028-12-31"},{"nctId":"NCT05019716","phase":"PHASE1,PHASE2","title":"Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-07-13","conditions":["Advanced NUT Carcinoma","Metastatic NUT Carcinoma","Unresectable NUT Carcinoma"],"enrollment":36,"completionDate":"2026-06-30"},{"nctId":"NCT06312137","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-03","conditions":["Non Small Cell Lung Cancer"],"enrollment":780,"completionDate":"2034-10-23"},{"nctId":"NCT07493980","phase":"PHASE2","title":"Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2026-03","conditions":["NSCLC Stage II"],"enrollment":54,"completionDate":"2029-01-01"},{"nctId":"NCT05001880","phase":"PHASE2","title":"Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-22","conditions":["Peritoneal Malignant Mesothelioma"],"enrollment":66,"completionDate":"2026-08-20"},{"nctId":"NCT06538038","phase":"","title":"Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients","status":"RECRUITING","sponsor":"PrECOG, LLC.","startDate":"2024-09-17","conditions":["Non Small Cell Lung Cancer","Epidermal Growth Factor Receptor Gene Mutation","Stage III Lung Cancer","Stage IV Lung Cancer"],"enrollment":538,"completionDate":"2029-08"},{"nctId":"NCT07281417","phase":"PHASE2","title":"Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-11-24","conditions":["Sinonasal Squamous Cell Carcinoma","Stage III Sinonasal Cancer AJCC v8","Stage IVA Sinonasal Cancer AJCC v8","Stage IVB Sinonasal Cancer AJCC v8"],"enrollment":108,"completionDate":"2030-12-16"},{"nctId":"NCT03871257","phase":"PHASE3","title":"A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-01-15","conditions":["Low Grade Glioma","Neurofibromatosis Type 1","Visual Pathway Glioma"],"enrollment":165,"completionDate":"2027-12-31"},{"nctId":"NCT05063552","phase":"PHASE2,PHASE3","title":"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-13","conditions":["Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Metastatic Head and Neck Squamous Cell Carcinoma","Metastatic Hypopharyngeal Squamous Cell Carcinoma","Metastatic Laryngeal Squamous Cell Carcinoma","Metastatic Lip and Oral Cavity Carcinoma","Metastatic Nasal Cavity Squamous Cell Carcinoma","Metastatic Nasopharyngeal Squamous Cell Carcinoma","Metastatic Pharyngeal Squamous Cell Carcinoma","Metastatic Sinonasal Squamous Cell Carcinoma","Recurrent Head and Neck Squamous Cell Carcinoma","Recurrent Hypopharyngeal Squamous Cell Carcinoma","Recurrent Laryngeal Squamous Cell Carcinoma","Recurrent Lip and Oral Cavity Squamous Cell Carcinoma","Recurrent Nasopharyngeal Squamous Cell Carcinoma","Recurrent Pharyngeal Squamous Cell Carcinoma","Recurrent Sinonasal Squamous Cell Carcinoma","Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8","Stage IV Hypopharyngeal Carcinoma AJCC v8","Stage IV Laryngeal Cancer AJCC v8","Stage IV Lip and Oral Cavity Cancer AJCC v8","Stage IV Nasopharyngeal Carcinoma AJCC v8","Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage IV Sinonasal Cancer AJCC v8"],"enrollment":430,"completionDate":"2027-12-15"},{"nctId":"NCT06096844","phase":"PHASE3","title":"Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-19","conditions":["Advanced Lung Non-Small Cell Carcinoma","Stage IIIB Lung Cancer AJCC v8","Stage IIIC Lung Cancer AJCC v8","Stage IV Lung Cancer AJCC v8"],"enrollment":304,"completionDate":"2026-06-01"},{"nctId":"NCT04267848","phase":"PHASE3","title":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-06-16","conditions":["Lung Non-Small Cell Carcinoma","Lung Non-Small Cell Squamous Carcinoma","Lung Non-Squamous Non-Small Cell Carcinoma","Stage II Lung Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIB Lung Cancer AJCC v8"],"enrollment":1210,"completionDate":"2027-01-31"},{"nctId":"NCT02194738","phase":"NA","title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-09-26","conditions":["Stage IB Lung Non-Small Cell Carcinoma AJCC v7","Stage II Lung Non-Small Cell Cancer AJCC v7","Stage IIA Lung Cancer AJCC v8","Stage IIB Lung Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIA Lung Non-Small Cell Cancer AJCC v7","Stage IIIB Lung Cancer AJCC v8"],"enrollment":8300,"completionDate":"2026-09-28"},{"nctId":"NCT03811002","phase":"PHASE3","title":"Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-26","conditions":["Limited Stage Lung Small Cell Carcinoma","Stage I Lung Cancer AJCC v8","Stage II Lung Cancer AJCC v8","Stage III Lung Cancer AJCC v8"],"enrollment":544,"completionDate":"2029-02-21"},{"nctId":"NCT06694454","phase":"PHASE1,PHASE2","title":"Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":["Non-small Cell Lung Cancer (NSCLC)","Carcinoma, Non-Small Cell Lung","Non-Small Cell Lung Carcinoma","Non Small Cell Lung Cancer","Non Small Cell Lung Carcinoma"],"enrollment":60,"completionDate":"2034-12-31"},{"nctId":"NCT06524544","phase":"PHASE3","title":"A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-12-02","conditions":["Locally Advanced Urothelial Carcinoma","Metastatic Urothelial Carcinoma","Unresectable Urothelial Carcinoma"],"enrollment":320,"completionDate":"2028-12-31"},{"nctId":"NCT05771480","phase":"PHASE3","title":"Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-08-16","conditions":["Biliary Tract Cancer"],"enrollment":142,"completionDate":"2026-09-17"},{"nctId":"NCT02905591","phase":"PHASE2","title":"A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Joseph J. Cullen, MD, FACS","startDate":"2018-11-16","conditions":["Carcinoma, Non-Small-Cell Lung","Non-Small Cell Lung Cancer","Nonsmall Cell Lung Cancer","Non-Small-Cell Lung Carcinoma","NSCLC"],"enrollment":43,"completionDate":"2027-12-31"},{"nctId":"NCT05555732","phase":"PHASE3","title":"Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2023-01-11","conditions":["Metastatic Non Small Cell Lung Cancer"],"enrollment":1170,"completionDate":"2029-05-11"},{"nctId":"NCT04994977","phase":"PHASE1","title":"Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2023-05-04","conditions":["Atypical Choroid Plexus Papilloma","Choroid Plexus Carcinoma"],"enrollment":1,"completionDate":"2025-12-01"},{"nctId":"NCT07138755","phase":"PHASE2","title":"The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients","status":"RECRUITING","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2025-08-29","conditions":["NSCLC","Sintilimab","Adaptive Radiotherapy"],"enrollment":35,"completionDate":"2030-09"},{"nctId":"NCT07492680","phase":"PHASE2","title":"A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)","status":"NOT_YET_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-07-17","conditions":["Solid Tumors"],"enrollment":260,"completionDate":"2032-05-20"},{"nctId":"NCT05108870","phase":"PHASE1,PHASE2","title":"TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers","status":"NOT_YET_RECRUITING","sponsor":"University of Chicago","startDate":"2026-07-17","conditions":["Human Papilloma Virus","HPV","HPV Positive Oropharyngeal Squamous Cell Carcinoma","Head and Neck Cancer"],"enrollment":98,"completionDate":"2027-01-01"},{"nctId":"NCT05806060","phase":"PHASE3","title":"Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-04-25","conditions":["Triple-Negative Breast Cancer"],"enrollment":134,"completionDate":"2026-11-01"},{"nctId":"NCT06333951","phase":"PHASE1","title":"AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-09-17","conditions":["Thoracic Tumors","Non-small Cell Lung Cancer"],"enrollment":500,"completionDate":"2031-10-27"},{"nctId":"NCT06119581","phase":"PHASE3","title":"A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2023-12-21","conditions":["Carcinoma, Non-Small-Cell Lung","Neoplasm Metastasis"],"enrollment":1264,"completionDate":"2031-01"},{"nctId":"NCT07173751","phase":"PHASE3","title":"ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-10-30","conditions":["Breast Neoplasms"],"enrollment":558,"completionDate":"2030-09"},{"nctId":"NCT07492342","phase":"PHASE2","title":"Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC","status":"RECRUITING","sponsor":"Jianxing He","startDate":"2026-01-29","conditions":["Resectable NSCLC","KRAS G12C Mutation","Stage IB-IIIA NSCLC","Neoadjuvant Therapy"],"enrollment":30,"completionDate":"2027-12-31"},{"nctId":"NCT07221474","phase":"PHASE2","title":"A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-12","conditions":["Squamous Non-small Cell Lung Cancer"],"enrollment":180,"completionDate":"2031-05-06"},{"nctId":"NCT06946797","phase":"PHASE2","title":"A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-09-19","conditions":["Non-Small Cell Lung Cancer"],"enrollment":76,"completionDate":"2028-10-25"},{"nctId":"NCT06926868","phase":"PHASE2,PHASE3","title":"A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-09-11","conditions":["Breast Neoplasms"],"enrollment":500,"completionDate":"2030-05-15"},{"nctId":"NCT04216316","phase":"PHASE1,PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-14","conditions":["Lung Non-Small Cell Squamous Carcinoma","Stage IV Lung Cancer AJCC v8"],"enrollment":12,"completionDate":"2026-05-08"},{"nctId":"NCT04095364","phase":"PHASE3","title":"Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2019-09-20","conditions":["Low Grade Fallopian Tube Serous Adenocarcinoma","Ovarian Low Grade Serous Adenocarcinoma","Primary Peritoneal Low Grade Serous Adenocarcinoma","Stage II Fallopian Tube Cancer AJCC v8","Stage II Ovarian Cancer AJCC v8","Stage II Primary Peritoneal Cancer AJCC v8","Stage III Fallopian Tube Cancer AJCC v8","Stage III Ovarian Cancer AJCC v8","Stage III Primary Peritoneal Cancer AJCC v8","Stage IV Fallopian Tube Cancer AJCC v8","Stage IV Ovarian Cancer AJCC v8","Stage IV Primary Peritoneal Cancer AJCC v8"],"enrollment":450,"completionDate":"2028-02-01"},{"nctId":"NCT06535607","phase":"PHASE2","title":"Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-22","conditions":["Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)","Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)","Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)","Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)","Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)"],"enrollment":257,"completionDate":"2028-11-30"},{"nctId":"NCT06323460","phase":"PHASE2","title":"Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2024-03-21","conditions":["Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Oropharyngeal Squamous Cell Carcinoma"],"enrollment":45,"completionDate":"2026-12-31"},{"nctId":"NCT04858269","phase":"PHASE2","title":"First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2021-05-27","conditions":["Head Neck Cancer","Metastatic Squamous Cell Carcinoma","Oral Cavity Squamous Cell Carcinoma","Oropharynx Squamous Cell Carcinoma","Hypopharynx Squamous Cell Carcinoma","Larynx Squamous Cell Carcinoma"],"enrollment":32,"completionDate":"2028-08"},{"nctId":"NCT07490002","phase":"PHASE2","title":"Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC","status":"NOT_YET_RECRUITING","sponsor":"Changhai Hospital","startDate":"2026-04-06","conditions":["Esophageal Squamous Carcinoma"],"enrollment":33,"completionDate":"2030-11-30"},{"nctId":"NCT06623422","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-10-21","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":680,"completionDate":"2038-01-26"},{"nctId":"NCT03288545","phase":"PHASE1,PHASE2","title":"A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2017-10-11","conditions":["Carcinoma, Transitional Cell","Urinary Bladder Neoplasms","Urologic Neoplasms","Renal Pelvis Neoplasms","Urothelial Cancer","Ureteral Neoplasms","Urethral Neoplasms"],"enrollment":348,"completionDate":"2026-02-20"},{"nctId":"NCT07491822","phase":"NA","title":"A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-03-25","conditions":["TNBC"],"enrollment":43,"completionDate":"2031-03-15"},{"nctId":"NCT06396065","phase":"PHASE3","title":"Phase III Study of AK112 for NSCLC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Summit Therapeutics","startDate":"2023-05-04","conditions":["Non-Squamous Non-small Cell Lung Cancer"],"enrollment":420,"completionDate":"2026-12-31"},{"nctId":"NCT03493425","phase":"PHASE2","title":"Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-03-12","conditions":["Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7","Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7"],"enrollment":82,"completionDate":"2029-03-31"},{"nctId":"NCT06667076","phase":"PHASE2","title":"A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-12-16","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":480,"completionDate":"2030-12-26"},{"nctId":"NCT06917079","phase":"PHASE1","title":"BBO-11818 in Adult Subjects With KRAS Mutant Cancer","status":"RECRUITING","sponsor":"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)","startDate":"2025-03-31","conditions":["Non-Small Cell Lung Cancer","NSCLC","PDAC - Pancreatic Ductal Adenocarcinoma","CRC (Colorectal Cancer)","Metastatic Non-Small Lung Cell Cancer","Metastatic Colorectal Cancer (CRC)","KRAS G12A","KRAS G12C","KRAS G12D","KRAS G12S","KRAS G12V","Metastatic Pancreatic Ductal Adenocarcinoma","Advanced Lung Carcinoma","Solid Tumor, Adult"],"enrollment":387,"completionDate":"2029-09"},{"nctId":"NCT04677816","phase":"PHASE2","title":"Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2021-10-22","conditions":["Triple Negative Breast Cancer","Vitamin D Deficiency","Invasive Breast Cancer"],"enrollment":50,"completionDate":"2026-08"},{"nctId":"NCT07486817","phase":"PHASE2","title":"Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab","status":"NOT_YET_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2026-05-08","conditions":["Lung Cancer, Non-squamous, Non-small Cell"],"enrollment":60,"completionDate":"2029-08-25"},{"nctId":"NCT06915025","phase":"PHASE3","title":"Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer","status":"RECRUITING","sponsor":"Imunon","startDate":"2025-07-09","conditions":["Epithelial Ovarian Cancer","Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Carcinoma"],"enrollment":500,"completionDate":"2032-10-31"},{"nctId":"NCT05903092","phase":"PHASE2","title":"MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer","status":"SUSPENDED","sponsor":"Hirva Mamdani","startDate":"2023-09-26","conditions":["Small Cell Lung Cancer","SCLC","Extensive Stage Small Cell Lung Cancer","Limited Stage Small-Cell Lung Cancer"],"enrollment":84,"completionDate":"2028-01-03"},{"nctId":"NCT03044613","phase":"PHASE1","title":"Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2017-07-11","conditions":["Gastric Cancer","Esophageal Cancer","GastroEsophageal Cancer"],"enrollment":32,"completionDate":"2027-08"},{"nctId":"NCT07005102","phase":"PHASE2,PHASE3","title":"A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-08-03","conditions":["Non-Squamous Non-Small Cell Lung Cancer"],"enrollment":854,"completionDate":"2036-11"},{"nctId":"NCT06897579","phase":"PHASE2","title":"Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-07","conditions":["Extensive Stage Small Cell Lung Cancer"],"enrollment":134,"completionDate":"2027-04"},{"nctId":"NCT06528691","phase":"PHASE2","title":"Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2026-04","conditions":["High Grade Glioma","CNS Tumor"],"enrollment":52,"completionDate":"2032-11"},{"nctId":"NCT05911295","phase":"PHASE3","title":"Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2023-09-22","conditions":["Urothelial Carcinoma"],"enrollment":412,"completionDate":"2029-04-30"},{"nctId":"NCT06493019","phase":"PHASE2","title":"Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer","status":"RECRUITING","sponsor":"Dustin Deming","startDate":"2024-09-30","conditions":["Anal Cancer"],"enrollment":23,"completionDate":"2029-04-14"},{"nctId":"NCT05980169","phase":"NA","title":"The Effect of Low Frequency Soundwave Stimulation on Chemotherapy Induced Peripheral Neuropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Augusta University","startDate":"2023-11-29","conditions":["Gynecologic Cancer","Neuropathy;Peripheral"],"enrollment":80,"completionDate":"2029-12-01"},{"nctId":"NCT04417088","phase":"PHASE1,PHASE2","title":"Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy","status":"COMPLETED","sponsor":"InSightec","startDate":"2020-11-06","conditions":["Recurrent Glioblastoma"],"enrollment":28,"completionDate":"2023-12-31"},{"nctId":"NCT06085729","phase":"PHASE1,PHASE2","title":"Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)","status":"SUSPENDED","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-02-29","conditions":["Prostate Cancer"],"enrollment":30,"completionDate":"2027-12-31"},{"nctId":"NCT07227597","phase":"PHASE1,PHASE2","title":"A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-29","conditions":["Small Cell Lung Cancer Extensive Stage"],"enrollment":170,"completionDate":"2030-12-30"},{"nctId":"NCT05700461","phase":"PHASE1","title":"Drug Screening Using Novel IMD in Renal Cell Carcinoma","status":"ENROLLING_BY_INVITATION","sponsor":"Oliver Jonas","startDate":"2024-12-01","conditions":["Renal Cell Carcinoma","Metastatic Renal Cell Carcinoma","Kidney Cancer"],"enrollment":20,"completionDate":"2029-08-31"},{"nctId":"NCT05027633","phase":"PHASE2","title":"Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-11-02","conditions":["Squamous Cell Carcinoma","the Nasal Cavity","Paranasal Sinuses"],"enrollment":35,"completionDate":"2028-03-30"},{"nctId":"NCT06831955","phase":"PHASE2","title":"LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2026-02-01","conditions":["Triple Negative Breast Cancer (TNBC), Early Setting"],"enrollment":356,"completionDate":"2031-09-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injection, Solution","formulations":[{"form":"INJECTION","route":"INTRAVENOUS","productName":"Carboplatin"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"PARAPLATIN"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"carboplatin"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"CARBOPLATIN"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"CARBOplatin"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Carboplatin"},{"form":"SOLUTION","route":"INTRAVENOUS","productName":"Carboplatin"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147598","MMSL":"3186","NDDF":"002643","UNII":"BG3F62OND5","VUID":"4019478","CHEBI":"CHEBI:31355","VANDF":"4019478","INN_ID":"5231","RXNORM":"152200","UMLSCUI":"C0079083","chemblId":"CHEMBL1351","ChEMBL_ID":"CHEMBL1351","KEGG_DRUG":"D01363","DRUGBANK_ID":"DB00958","PDB_CHEM_ID":" QPT","PUBCHEM_CID":"426756","SNOMEDCT_US":"108759002","IUPHAR_LIGAND_ID":"7624","MESH_DESCRIPTOR_UI":"D016190"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Avyxa Holdings","relationship":"Current Owner"},{"period":"2021","companyName":"MYLAN SEIYAKU Ltd","relationship":"PMDA Licensee"}],"pharmacokinetics":{"tmax":"","halfLife":"Alpha phase: 1.1 to 2 hours; Beta phase: 2.6 to 5.9 hours; Platinum-bound species: minimum 5 days","clearance":"4.4 L/hour total body clearance","excretion":"Renal excretion is the major route; 65% of dose excreted in urine within 12 hours and 71% within 24 hours in patients with creatinine clearance ≥60 mL/min","metabolism":"","proteinBinding":"Carboplatin is not bound to plasma proteins; however, platinum from carboplatin becomes irreversibly bound to plasma proteins","bioavailability":"","volumeOfDistribution":"16 L apparent volume of distribution"},"publicationCount":20073,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01XA02","allCodes":["L01XA02"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 10","pmid":"41899495","title":"Obesity and Tolerance to Neoadjuvant Chemotherapy in Breast Cancer: A Retrospective Cohort Study.","journal":"Cancers"},{"date":"2026 Mar 19","pmid":"41899267","title":"Primary Peritoneal Low-Grade Serous Carcinoma in a 16-Year-Old Female: A Case Report.","journal":"Journal of clinical medicine"},{"date":"2026 Mar 20","pmid":"41898678","title":"NRF2 Drives Aggressiveness and Chemoresistance in Ovarian Cancer Stem-like Cells.","journal":"International journal of molecular sciences"},{"date":"2026 Mar 10","pmid":"41898390","title":"Radiobiological Effects of Low-Dose Radiation in Normal Fibroblasts of Patients with Head and Neck Cancer Treated with Induction Chemotherapy Combined with Low-Dose Fractionated Radiation.","journal":"International journal of molecular sciences"},{"date":"2026 Mar 11","pmid":"41897350","title":"Metformin-A Type 2 Diabetes Mellitus Drug-And Ovarian Cancer: Anticancer Mechanisms and Therapeutic Implications.","journal":"Biomolecules"}],"companionDiagnostics":[],"genericManufacturers":23,"_genericFilersChecked":true,"genericManufacturerList":["Accord Hlthcare","Actavis Totowa","Cipla Ltd","Epic Pharma Llc","Eugia Pharma","Fresenius Kabi Usa","Gland","Hikma","Hospira","Meitheal","Natco Pharma Usa","Novast Labs","Pharmachemie Bv","Pharmobedient","Pliva","Pliva Lachema","Qilu Pharm Hainan","Sandoz","Sun Pharm","Teva Parenteral","Teva Pharms Usa","Teyro Labs","Watson Labs Teva"],"status":"approved","companyName":"Avyxa Holdings","companyId":"mylan-seiyaku-ltd","modality":"Small molecule","firstApprovalDate":"1989","enrichmentLevel":5,"visitCount":9,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2006-02-15T00:00:00.000Z","mah":"FRESENIUS KABI USA","brand_name_local":null,"application_number":"ANDA077266"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2007-01-18T00:00:00.000Z","mah":"TEYRO LABS","brand_name_local":null,"application_number":"ANDA077861"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2007-12-28T00:00:00.000Z","mah":"PHARMACHEMIE BV","brand_name_local":null,"application_number":"ANDA077269"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-02-15T00:00:00.000Z","mah":"GLAND","brand_name_local":null,"application_number":"ANDA207324"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-08-08T00:00:00.000Z","mah":"AVYXA HOLDINGS","brand_name_local":null,"application_number":"NDA219921"},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":694,"withResults":324},"validation":{"fieldsValidated":5,"lastValidatedAt":"2026-04-20T08:35:21.079866+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}